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Thesis supervised by Dr. Kevin Tidgewell 
 This thesis describes the isolation, structure elucidation, and synthesis of natural products 
from marine cyanobacteria. A crude extract from a cyanobacterium collected in Curacao showed 
selective affinity for the dopamine D5 receptor in a screen against a panel of CNS receptors. Due 
to the high similarity of the D5 and D1 receptor, to date there are no known ligands that 
differentiate them. Attempts to purify the compound responsible for this affinity led to the 
isolation of the known compound caylobolide A. A second extract from a cyanobacterium 
collected in Panama underwent bioassay-guided fractionation and yielded the novel compound 
naranjamide, which showed activity against P. falciparum the protozoa responsible for malaria. 
Syntheses of naranjamide and its nonmethylated analog were attempted in order to verify the 
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“All that man needs for health and healing has been provided by God 







1.1. A Brief History of Natural Products  
Since ancient times, civilizations have used plants and plant extracts for healing and 
ameliorating diseases. Historical writings, such as Ebers Papyrus dating back to 1552 BC 
of Ancient Egypt, and others dating as far back as 5000 BC Mesopotamia, described 
using plants to determine pregnancy and to ease labor.1 Other important historical 
marks include the discovery of the beneficial effects of cardiotonic digitalis extracts from 
foxglove for treatment of heart disease symptoms, the use of willow and cinchona tree 
bark for the treatment of fever, and the discovery of the effectiveness of poppy extracts 
in the treatment of dysentery.2   
In 1810, the term pharmacognosy was coined, describing the study of nature as a source 
of drugs in a book titled Anglecta Pharmacognostica. Throughout the 19th century, with 
improvements in technology, isolating and identifying the active compounds from their 
natural producers became possible, and common. Morphine [figure 1A], responsible for 
the analgesic and sedative effects of opium, was isolated from the seed capsules of the 
poppy plant in 1804. Caffeine [figure 1A], a natural pesticide produced in plants, was 
isolated in 1819 by Friedlieb Ferdinand Runge, and its structure determined in 1897 by 
Hermann Emil Fischer. Runge also discovered quinine [figure 1A] from the bark of the 
cinchona tree, still used today to treat malaria. By 1829, scientists discovered that salicin 
[figure 1A] was responsible for the pain relief seen from ingesting willow bark extract, 
and in 1838 salicylic acid [figure 1A] was isolated. However, salicylic acid was found to 
be harsh on the stomach, and in the second half of the 19th century, acetylsalicylic acid 
[figure 1A] was synthesized, providing a less irritating replacement for the original 




antibacterial compound produced by Penicillium chrysogenum growing on a petri dish 
containing Staphylococci bacteria. The structure was confirmed by X-ray in 1945 by 
Dorothy Crowfoot Hodgkin. The advances in analytical technology has allowed us to 
understand the effects of traditional medicine, to isolate and replicate the active 
ingredient, and to formulate and market it as modern medicine. Pharmacognosy is now 
described by the American Society of Pharmacognosy as the study of natural product 
molecules from sources of all biological kingdoms, most notably marine invertebrates, 
plants, fungi, and bacteria, that are useful for their medicinal, ecological, gustatory, or 
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1.2. Natural Products 
Natural products are also known as secondary metabolites, compounds that are 
naturally produced by biological organisms. Unlike primary metabolites, which are 
indispensable and absolutely required for survival (i.e. carbohydrates, fats, proteins, and 
nucleic acids), these natural products are not directly involved in the normal growth, 
development, or reproduction of the organism. While an absence of them does not result 
in immediate death, these secondary metabolites can affect the organism’s fitness by 
playing a role in protection, competition, and inter- and intraspecies interactions.  
Natural products have a broad range of functions. These functions include agents that 
solubilize and transport nutrients, like siderophores which transport iron Fe+3 across 
membranes in bacteria and fungi; pheromones that act as social signaling molecules 
with other individuals of the same species, like queen mandibular pheromone secreted 
by the queen bee to feed her attendants that gives the colony a sense of belonging; 
communication molecules that attract and activate symbiotic organisms, like maltose 
released from chlorella algae to its cnidarian host;3 and chemical agents that are used 
against competitors, prey, and predators, like the acacia trees which produce tannins in 
their leaves when they’re preyed upon by giraffes. For many other compounds, the 
ecological and/or biological function is still unknown. 
Natural products are often structurally complex molecules that possess a well-defined 
spatial orientation. These compounds have evolved to interact efficiently with their 
biological targets, as their producers evolved alongside their target organisms. These 
natural products have effect in human health as well; in fact, it was the identification of 




cannabinoid receptors in the 1990s.4 Research of these receptors and natural 
cannabinoids led to the development of drugs for stimulation of appetite and 
amelioration of nausea as well as symptomatic relief of cancer pain,5 proving that these 




1.3. Marine Natural Products 
With centuries of terrestrial pharmacognosy, scientists have more recently started 
looking into the oceans and other aquatic environments as untapped sources of natural 
products. The Ocean covers over 70% of the Earth’s surface and contains an estimated 
95% of the Earth’s biosphere. According to fossil records, living organisms first 
appeared in the sea more than 3.5 billion years ago.6 Over time, they evolved many 
different physical and chemical mechanisms to survive various environments, including 
extreme temperature, salinity, pressure, oxygen levels, and sunlight, to overcome effects 
of mutation, and to survive infection, fouling, and overgrowth of other organisms. For 
immobile organisms, chemical adaptations would need to be extremely potent due to 
the diluting effect of the ocean water. 
The diverse chemical features and wide range of biological activities of marine natural 
products have established them as a source of chemodiversity.7-8 With recent advances 
in technology, including SCUBA (self-contained underwater breathing apparatus) and 
submersible ROVs (remotely operated vehicles), shallow water and deep sea organism 
collections are now possible. Purified compounds from these collections are now able to 
be detected in sub-milligram quantities with the help of modern analytical equipment. 
Improvements in organic chemistry strategies enable practical syntheses of these 
diverse natural products. These available technologies have made discovery, structure 
elucidation, and synthesis of natural products from marine sources a more feasible and 
attainable goal. 
To date, more than 30,000 publications have been listed in the major database of 




community towards the discovery of new drug leads from marine habitats. According to 
the latest review by Carroll,10 1490 new compounds were isolated from marine 
organisms in 2017, a number which has risen steadily from the beginning of the century 
[figure 1B].  
 
 
Figure 1B: Number of Marine Natural Products Discovered by Year10-25 
 
 
1.3.1. Marine Natural Products: Biologically Active Compounds 
Marine natural products display a superior chemical novelty when compared with 
terrestrial natural products. Kong et al26 compared molecular scaffolds in the Dictionary 
of Natural Products to those in the Dictionary of Marine Natural Products, and showed 
that approximately 70% of molecular scaffolds in the Dictionary of Marine Natural 
Products are exclusively utilized by marine organisms. Marine natural products usually 
possess more long chains and large rings, especially 8- to 10-membered rings. Marine 

































fewer oxygen atoms, suggesting that marine natural products may be synthesized by 
more diverse biosynthetic pathways than terrestrial natural products.27 
This chemodiversity is reflected by varied biological activity, and has led to several 
approved drugs from marine sources.28-29 Cytarabine and vidarabine [figure 1C] were 
the first FDA-approved marine-derived drugs, consisting of an arabinose sugar paired 
with pyrimidine and purine nucleosides, respectively. They were developed from 
naturally occurring nucleosides originally isolated from the Caribbean sponge Tethya 
crypta, namely spongouridine and spongothymidine [figure 1C], consisting of thymine- 
and uracil-arabinose, respectively. Both of the synthetic nucleosides can incorporate 
into the DNA, however, the arabinose ring in the synthetic drugs prevents the DNA 
strand from growing, therefore, killing the cell. The drugs are used for cancer therapy, 
and vidarabine is also used in herpes virus infections. Trabectedin [figure 1C], a marine 
alkaloid isolated from the tunicate Ecteinascidia turbinate, gained EU approval for the 
treatment of soft tissue sarcoma. It acts by blocking DNA binding of the oncogenic 
transcription factor FUS-CHOP. Eribulin mesylate [figure 1C], a structurally simplified 
macrocyclic ketone analog of the potent cytotoxic compound halichondrin B first 
isolated from the marine sponge Halichondria okadai in 1986, is FDA approved for 
metastatic breast cancer. Eribulin acts by binding to and inhibiting microtubule 
dynamics. Ziconotide [figure 1D], a synthetic equivalent of the naturally occurring ω-
conotoxin peptide isolated from cone snail (Conus magus) venom, was approved for 
severe chronic pain management. It is an N-type voltage-gated calcium channel blocker, 
inhibiting the release of pro-nociceptive neurochemicals in the brain and spinal cord, 
resulting in pain relief 1000 times more efficacious than morphine. These are just some 































1.4. Marine Cyanobacteria 
“Water blooms” in freshwater lakes were reported in literature as early as the 1930s to 
produce toxins that had negative effects on human and animal health, causing 
“swimmers’ itch” to those who bathed, and illness and even death to animals who 
ingested the water.30 It was this phenomenon that led Richard E. Moore to pioneer the 
investigation of marine blooms of what was thought to be “blue-green algae”, leading to 
the discovery of majusculamides A and B [figure 1E] from blooms of Lyngbya 
majuscula Gomont, a marine cyanobacteria, in 1977.31 
 
 
Figure 1E: Majusculamide A/B 
 
Cyanobacteria are a phylum of prokaryotic bacteria with fossil records dating back to 3.5 
billion years ago. They inhabit diverse environments, including fresh and saline waters, 
terrestrial deserts and forests, and other extreme environments. Their name derives 
from their color, which allows them to perform oxygenic plant-like photosynthesis, with 
autotrophy as their dominant form of nutrition. Some cyanobacteria can grow in 




have the ability to fix atmospheric nitrogen. These capabilities, along with their different 
environmental surroundings, allow cyanobacteria to synthesize a vast collection of 
varying organic compounds.  
Another reason for their natural product diversity is their genome size. Unicellular 
cyanobacteria of the chroococcales order have genome sizes of 1.7-4.0 Mbp, similar in 
size to those of other bacteria. However, higher orders of cyanobacteria, including 
filamentous orders oscillatoriales and nostocales, possess larger genomes of up to 6.0-10 
Mbp,32 up to five times as large as other bacteria. Data suggests that genome evolution 
and the relatively larger genome size in cyanobacteria occurred by a series of 
duplications of a small ancestral genome,33 whereas horizontal gene transfer has also 
been thought to contribute to the size and variety of their genomes.34 A larger genome 
would allow to produce a wider range of enzymes, enabling cyanobacteria to synthesize 
an assortment of organic compounds.  
Cyanobacteria, with their diverse habitats and large genome, can produce a multitude of 
natural products that contribute to their fitness. Being sessile organisms in the open 
shallow waters, these natural products would need to be extremely potent to be effective 
and beneficial. It is these reasons that scientists are investigating these organisms and 
their chemical makeup, isolating interesting and complex secondary metabolites and 






1.4.1. Natural Products from Marine Cyanobacteria 
Of the hundreds of compounds discovered from the ocean each year since 2011, 
cyanobacterial natural products account for 2.3% of the total compounds discovered. In 
2017, of the 1490 total compounds discovered from the ocean, 48 new compounds were 
of cyanobacterial origin (3.2%).10 
Cyanobacteria produce a wide variety of different metabolites. Molecular weight 
distribution of known cyanobacterial compounds shows a bell-shaped curve, peaking 
around the 400-500 kDa range [figure 1F], correlating to the range of drug-like 
molecules, according to the Lipinski rules.35 Structural classes from cyanobacteria 
include saccharides and glycosides, terpenes, fatty acids, polyketides, non-ribosomal 
peptides, and ribosome post-translationally modified peptides. 
 
 



































1.4.1.1. Saccharides & Glycosides 
Cyanobacteria have rarely been reported to produce exclusively sugar-based secondary 
metabolites. However, this may be due to the extraction technique used by many natural 
product chemists that study cyanobacterial metabolites, who do not focus on water-
soluble metabolites, as standard extraction and isolation procedures select against the 
isolation of polar, sugar-based compounds. 
An example of a sugar-based metabolite from cyanobacteria is cyclodextrin [figure 
1G],36 isolated from a Hawaiian Tolypothrix byssoidea strain. This molecule, along with 
a range of related metabolites produced, was found to have protective properties of 
other toxic metabolites produced by this cyanobacterium. 
 
1.4.1.2. Terpenes 
Terpenes are a class of hydrocarbon compounds, constructed from isoprene units that 
are combined to produce a variety of carbon-based skeletons, which can then be acted 
upon by various enzymes to add functionality, such as cyclizations and oxidations. 
Terpenes include the large structural groups of steroids and carotenoids, and have a 
broad variety of functions, including incorporating into cellular wall structures. 
An example of a cyanobacterial terpene is tolypodiol [figure 1G],37 a meroditerpene 
isolated from a cultured sample of Tolypothrix nodosa originally collected from a soil 







Polyketides are a class of compounds created by polyketide synthases (PKS). The type I 
PKS system found in cyanobacteria includes a series of catalytic domains linked together 
that transfer  and condense  chains of acetate or propionate units, and then modify them 
primarily via carbonyl reduction, dehydration into a cis-alkene, reduction into an 
alkane, and finally cleavage of the chain to form the final compound. Additional 
functionalizations like oxidations and cyclizations can occur as well.  
Amantelide A [figure 1G] is an example of a cyanobacterial polyketide, which consists of 
a 40-membered macrolactone ring, featuring a 1,3-diol and contiguous 1,5-diol units, 
with a tert-butyl substituent. Amantalide A displayed potent cytotoxicity with 
submicromolar IC50 against HT-29 colorectal adenocarcinoma and HeLa cervical 
carcinoma cell lines, as well as antibacterial and antifungal activity.38 
 
1.4.1.4. Fatty Acid Derivatives 
Fatty acids and fatty acid derivatives from cyanobacteria are created by the type II fatty 
acid synthase (FAS), a series of enzymes that act similarly to those of the type I PKS, but 
are separate catalytic units. The products synthesized are diverse in terms of size, degree 
of saturation, patterns of unsaturation, alkylation, and hydroxylation. Often, fatty acids 
are incorporated as sections within complex cyanobacterial natural products.  
One of the more bioactive fatty acid derivatives from cyanobacteria is lyngbic acid 
[figure 1H], which possesses low micromolar antifungal and cancer cell cytotoxic 








Cyanobacteria produce a wide range of peptides and other amino acid-derived 
metabolites. They range in size from conjugated amino acid pairs to polypeptides of over 
1800 kDa. The majority of amino acids incorporated into cyanobacterial secondary 
metabolites are nonpolar, with the second highest class being polar noncharged amino 
acids, and most often in the L-form. Cyanobacteria can incorporate non-standard amino 
acids, such as D-lysine, 3-amino-6-hydroxy-2-piperidone (Ahp), and homotyrosine 
[figure 1H]. About half of the time, the amino acids are incorporated without 
modifications; other times they include modifications like N- and O-methylation, 
sulfation, halogenation, oxidation, cyclization, and polyketide extension. Common N-
termini include N,N-dimethylation, usually on valines. C-termini include a variety of 
special caps, like dolaphenine as seen in naranjamide and barbamide, and a benzyl-
methoxypyrrolinone moiety, as seen in belamide A and caldoramide [figure 1H]. Both of 
these specialized caps are composed of two condensed amino acids. These structural 
features are typical of non-ribosomal peptides, which are synthesized by non-ribosomal 
peptide synthetase (NRPS) domains. 
Belamide A41 [figure 1H] is a highly methylated peptide composed of five amino acids. It 
was shown to disrupt the microtubule network in A-10 cells at 20 µM, and has an IC50 of 




methylated peptide with the same C-terminal cap as seen in belamide A. It was found to 
be active against HCT-116 colon cancer cells, with an IC50 of 3.9 µM. 
 
1.4.1.6. Mixed Biosynthetic Molecules 
Cyanobacteria are known for their ability to “mix & match” their syntheses.  
Dolastatin 10 [figure 1I], probably the most famous of cyanobacterial natural products, 
is composed mainly of peptides with added polyketide extension throughout the 
molecule. It was isolated in 1993 and named after the sea hare Dolabella auricularia it 
was initially extracted from. The peptide was present in very low yield, and ultimately, in 
2001, it was discovered to be a product of the sea hare’s diet of marine cyanobacteria, in 
particular the Symploca species.43 Dolastatin 10 has many closely related analogs, both 
natural and synthetic. Dolastatin 10 and symplostatin 1 [figure 1I], differing only by 
changing a valine to an isoleucine, are both potent microtubule inhibitors, thus 
disturbing the normal cell division process. Dolastatin 10 reached a phase II clinical 
trial, but was eventually unsuccessful due to its peripheral toxicity. It was ultimately 
developed as an anti-body drug conjugate and was approved by the FDA in 2011 for 
treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma 
as brentuximab vedotin (Adcetrix ®) [figure 1I].7 Dolastatin 10 is composed of several 
amino acids, including a terminal N,N-dimethyl valine, and an adjacent pair of ketide-
extended residues, isoleucine and proline. In both cases, these ketide-extended residues 
are reduced in their β-ketone functionality to the alcohol, and then O-methylated. The 




Largazole [figure 1I] is an example of a lipopeptide, composed of several unusual 
structural elements, including two polyketide sections connected through a thioester, a 
condensed cysteinyl-alanyl unit, which forms a thiazole ring, and a 4-methyl thiazoline 
ring formed from a second cysteine residue. This was the first thioester linkage observed 
in cyanobacterial natural products.32 Largazole shows exceptional antiproliferative 
activity with IC50 values to transformed cell lines in the low nanomolar range. Non-
transformed cells were much less sensitive to the molecule, suggesting a drug target 
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“This is the chemical formula for love: 
C8H11NO2 + C10H12N2O + C43H66N12O12S2 
Dopamine + Serotonin + Oxytocin 
It can be easily manufactured in a lab, but overdosing on any of them 







Dopamine has an important role as a neurotransmitter by interacting with its receptors 
in the CNS, which control a variety of functions, including learning, reward, motivation, 
emotion, memory, cognition, feeding, sleep, and locomotion. Dysfunction in the 
dopaminergic system is associated with several pathologies, including Parkinson’s 
disease, schizophrenia, depression, and addiction. Peripherally, these receptors are also 
involved in hormonal regulation, cardiovascular function, renal function, and olfaction, 
among others. 
 
2.1.1. Dopamine Receptors 
There are five dopamine receptors that belong to the class A of rhodopsin-like GPCRs,44 
which are characterized by the presence of seven α-helical transmembrane domains. 
These receptors have been classified into two families, the D1-like and D2-like receptors, 
depending on sequence homology, their association with G proteins, and their 
pharmacology.45 D1-like receptors (D1 and D5) are almost exclusively localized post-
synaptically on neurons, have a long C-terminal tail, do not contain introns, and have a 
short third cytoplasmic loop, and are coupled to G-protein subunits Gαs and Gαolf, which 
activate AC and lead to cAMP production and activation of PKA. The D5 receptor is also 
suggested to couple to Gαq. D2-like receptors (D2, D3, and D4) are found both pre- and 
post-synaptically, have a short C-terminal tail, contain up to six introns, and have a long 
third cytoplasmic loop, and are coupled to Gα i/o/z, and inhibit AC, limiting cAMP 




Evolutionarily, the two dopamine classes originated independently, such that the ability 
to bind dopamine was acquired twice during the evolution of biogenic amine receptors. 
It is suggested that these amine receptors, including the dopamine receptors, likely 
appeared before the cnidarian divergence, and that the D1-like or D2-like divergence 
from the ancestor took place before the separation of platyhelminthes,50 or in other 
words, before the divergence into symmetry, after the appearance of tissue 
compartmentalization. These would also be the first phyla to gain motility, allowing 
intentional hunting for prey. It appears that neither cnidaria nor platyhelminthes prey 
on cyanobacteria, perhaps because of the natural products cyanobacteria produce that 
could deter the organisms.  
 
2.1.2. Dopamine D5 Receptors 
In 1991, three genes closely related to the D1 receptor were identified in the human 
genome.51 One of the genes lacked introns and encoded a functional human dopamine 
receptor, D5, whose deduced amino acid sequence is 49% identical to that of the human 
D1 receptor. The D5 receptor displays a higher affinity and efficacy for dopamine 
compared to the D1 receptor, and unlike the D1 receptor, is constitutively active.51 A 
series of experiments showed that the C-terminus of the D5 receptor is responsible for 
the constitutive activity of the receptor, which has only 30% sequence homology to the 
D1 C-terminus.52 The transmembrane regions of the receptors, where ligands tend to 
bind, however, share nearly 80% of their sequence, making selective ligands difficult to 




Despite being transcribed by two distinct genes, little is known regarding the molecular 
determinants that modulate the functional properties of these two receptors. This is in 
large part due to the relatively low expression levels of D5 receptors in neuronal 
populations when compared to the widely distributed and more abundant D1 receptor. 
Another reason is the lack of available pharmacological tools and ligands that can 
selectively differentiate these receptors. In fact, most studies have utilized knockout 
models to determine the effect of the D5 receptor. It is therefore important to find D5-
selective molecules that will aid in studying the characteristics and functions of the D5 
receptor. 
 
2.1.3. Dopamine D5 Receptor Functions 
The D5 receptor was recently found to be expressed in human pituitary adenomas, 
glioblastomas, colon cancer, and gastric cancer. Activation of the receptor with an 
agonist in these cell lines suppressed their growth, inhibited MTOR activity, and 
induced autophagy.53 The efficacy was correlated with levels of D5 expression. 
The D5 receptor is widely expressed in the cerebral cortex and hippocampus, regions 
critically involved in spatial working memory function. Disruption of the dopamine D5 
receptor has been shown to impair spatial working memory and temporal order memory 
function, all of which are higher order cognitive functions associated with the prefrontal 
cortex. D5 knockout mice displayed impaired performance compared to their wildtype 
littermates when a higher burden on working memory faculties was imposed. In 




significant memory deficits, as did the complete knockout mice. Locomotion and 
motivation did not appear to be D5 dependent in this study.54 
Dopaminergic neurons are known to play a critical role in pain modulation in several 
areas of the CNS. D1-like receptors play an essential role in hyperalgesic priming, and 
are likely stimulated by the dopaminergic projections from the hypothalamus. Genetic 
ablation of the D5 receptors reduces acute pain responses and prevents hyperalgesic 
priming in a sex-dependent manner, affecting male, but not female, mice. Male D5 
knockout mice displayed decreased basal heat sensitivity and decreased responsiveness 
to irritant injection but had normal mechanical sensitivity. D5 mRNA expression was 
also higher in the spinal cord of male mice compared to females. Genetic ablation of the 
D1 receptor showed the opposite sex-dependent effects, affecting only female mice.55 
 
2.1.4. Natural Products for Dopaminergic Disorders 
There are several known plant natural products that are known to affect the 
dopaminergic receptors. Antagonist levo-tetrahydropalmatine56 (L-THP) [figure 2A] is 
found in both Corydalis genus and Stephania rotunda plants, and has been used in 
traditional Asian medicine for its analgesic, sedative, and hypnotic properties. More 
recently it has shown potential as an anti-craving agent.57 Mucuna pruriens is the best-
known natural source of levodopa (L-DOPA) [figure 2A], a dopamine agonist, the gold 
standard for treatment of Parkinson’s disease caused by an underactive dopaminergic 
system. These plants also produce 5-hydroxy tryptamine (serotonin) and psychedelic 5-
methoxy-N,N-dimethyl tryptamine.58 (-)-stepholidine59 (SPD) [figure 2A] from the 




described as a D1 partial agonist and D2 antagonist. Its unique dual effects suggest that it 
can restore the imbalance seen between D1 and D2 receptors in schizophrenic 
conditions, improving both the positive and negative symptoms of schizophrenia. It has 
also been shown that SPD can relieve the motor symptoms of Parkinson’s disease when 




L-THP L-DOPA (-)-SPD 
 
Figure 2A: Dopaminergic Natural Products from Plants 
 
2.1.5. Cyanobacterial Natural Products as Dopaminergic Ligands 
At the time of writing this thesis, there are no known cyanobacterial compounds that 
show effect on the dopamine receptors.  
There has been little investigation of marine cyanobacterial natural products as ligands 
for dopamine receptors; the majority of marine cyanobacterial extracts and compounds 
discovered are primarily tested in cancer, antibiotic, and other toxicity-based assays for 
activity. While cyanobacteria lack dopaminergic receptors, they do incorporate the 
amino acid tyrosine, the precursor to dopamine, into their secondary metabolites; 
dopamine receptors first appeared just a short time later on the evolutionary scale. It is 






2.2. Cyanobacterial Natural Products as D5 Receptor Ligands  
Our lab tests all cyanobacterial extracts obtained against a wide panel of CNS receptors 
at the PDSP. Several extracts have shown activity against one or more of the five 
dopamine receptors. One of our extracts, with its nine fractions, showed consistent 
activity at the dopamine D5 receptor, but not the D1 receptor, in seven of the eight 
fractions sent for PDSP testing. These fractions piqued my interest, because at present, 
there are no fully selective D5 ligands, because of its similarity to the D1 receptor 
previously mentioned. These fractions were therefore chosen to be purified in attempts 
to isolate the compound(s) responsible for the D5 activity. 
 
2.2.1. Collection, Extraction, & Fractionation 
A 150 mL sample of cyanobacterium was collected in June 2015 at a depth of 5-10 feet 
off the coast of Cas Abao, Curacao, and given the collection code CUCA-060415-7. It was 
described as a red filamentous mat in the sand. The cyanobacterial sample was put in a 
mix of 1:1 sea water and ethanol immediately upon collection, and later stored in -20°C 
upon return from Curacao to Pittsburgh.  
In September 2016, the 150 mL sample of the cyanobacterium was extracted using 
DCM:MeOH 2:1 for 30 minute soaks five times, and an additional soak was left 
overnight at room temperature. The aqueous phase was separated from the organic 
phase, which was dried and evaporated in vacuo to afford 662 mg of an oily crude 
extract, given the internal code DUQ0024. The extract was then subjected to flash liquid 





DUQ Mass [mg] Hexanes EtOAc MeOH 
0024A <4 100   
0024B 8 80 20  
0024C 39.2 60 40  
0024D 45.9 40 60  
0024E 28.1 20 80  
0024F 3.3  100  
0024G 6.7  75 25 
0024H 128.9  50 50 
0024i 265.7  0 100 
Table 2A: Fractionation Method of DUQ0024 and Masses Per Fraction 
 
2.2.2. Psychoactive Drug Screening Program Assay 
The initial fractions (0024B-i) were sent to PDSP for testing (0024A had less than 4 mg 
of material and was not sent) on a variety of CNS receptors, including the five dopamine 
receptors (D1-5) and dopamine transporter (DAT). The extracts were first subjected to a 
primary binding assay at a single concentration of 10 µg/mL to compete with the radio-
labeled ligand [table 2B and 2C]. If the ligand is inhibited by 50% or more, the extract is 
subjected to a secondary binding assay, where it is tested at 11 different concentrations 
to determine the IC50 value, the value where the extract inhibits ligand binding at 50% 
[table 2D and 2E]. [See section 2.4.5. for additional information on the PDSP assay.]  
DUQ D1 D2 D3 D4 D5 DAT 
0024B -6 -2 7 0 48 -55 
0024C -1 10 15 3 64 9 
0024D 28 21 28 10 77 9 
0024E 22 11 23 20 81 0 
0024F 3 -6 16 8 76 4 
0024G 3 -18 10 -1 70 -2 
0024H 12 5 15 6 70 12 
0024i 15 4 20 -3 50 -20 





DUQ 5HT2A 5HT3 M2 M3 M4 MOR NET SERT σ1 σ2 
0024B -13 -13 18 -10 23 2 -9 -18 34 11 
0024C 8 -2 -51 -24 -60 10 -10 -13 37 71 
0024D 35 32 7 -7 35 61 -12 4 4 53 
0024E 54 3 6 0 36 22 -5 17 44 48 
0024F 67 -21 11 19 17 36 -39 8 61 55 
0024G 38 -10 7 -2 17 35 -34 2 42 41 
0024H 28 -28 -7 -9 10 27 -82 -13 28 42 
0024i 17 -43 3 -2 45 2 -56 -54 39 32 
Table 2C: % Inhibition of Other Receptors and Transporters 
 
DUQ D1 D2 D3 D4 D5 DAT 
0024B      >10000 
0024C     3465  
0024D     2163  
0024E     2121  
0024F     1742  
0024G     2740  
0024H     2631  
0024i     3029  
Table 2D: IC50 [ng/mL] Against Dopaminergic Receptors and Transporter 
 
DUQ 5HT2A 5HT3 M2 M3 M4 MOR NET SERT σ1 σ2 
0024B           
0024C   >10000 >10000 >10000     3693 
0024D      2503    2605 
0024E 5077          
0024F 4015 5348     3258  >10000 1289 
0024G       2797    
0024H  7781     4605    
0024i  8611     2054 >10000   
Table 2E: IC50 [ng/mL] Against Other Receptors and Transporters 
 
Fractions 0024C-i showed activity of over 50% inhibition of the dopamine D5 receptor, 




is the reason that this extract was chosen to be further fractionated and explored for 
pure compounds that would contain these properties and be responsible for this activity.  
 
2.2.3. Isolation Procedure 
Fractions 0024H and 0024i were chosen to be subjected to further purification for three 
reasons: their larger size making isolation of enough material for structure elucidation 
more likely, NMR data showing peaks in the aromatic region correlating to 
dopaminergic ligands which require an aromatic moiety [figure 2B], and their mass 
spectrometry with molecular weights in the 700-800 region which falls under the small-
molecule molecular weight of drugs [figure 2C]. 
 
 











Figure 2C: MS of Fractions 0024H and 0024i 
 
2.2.3.1. Fraction 0024H 
Fraction 0024H, eluting with 50% MeOH in EtOAc, was subjected to normal phase 
column chromatography, using a gradient of 0-100% MeOH in DCM and yielding seven 
fractions (0024H1-7). Fraction 0024H6, with peaks in the aromatic region of the 1H-
NMR, was subjected to a reverse phase column, using a gradient of 30-100% MeOH in 
H2O, yielding five fractions (0024H6A-E). Fraction 0024H6E, with the same peaks in 
the aromatic region seen in 0024H6, was subjected to additional purification using 
normal phase column chromatography, using a gradient of 0-100% MeOH in DCM. 
Fraction 0024H6E4 [see figure 2D for fractionation details and figure 2E for 1H-NMR 
spectra] yielded what seemed like a pure compound, and was subjected to detailed 
analysis with a variety of NMR experiments. It was then concluded that the fraction was 
not of a pure compound, and that the peaks in the aromatic region did not belong to the 















2.2.3.2. Fraction 0024i 
At the same time, fraction 0024i, eluting with 100% MeOH, was subjected to normal 
phase column chromatography, using a gradient of 0-100% MeOH in DCM, yielding 
seven fractions (0024i1-7). Fraction 0024i5, with the same peaks in the aromatic region 
of the 1H-NMR as seen in 0024H6E4, was subjected to another normal phase column, 
using a gradient of 0-100% MeOH in EtOAc, with a slower gradient between 20-60% 
MeOH where 0024i5 eluted in the previous column, yielding seven fractions (0024i5A-
G). The 1H-NMR of fraction 0024i5F showed an 1H-NMR similar to that seen for 
0024H6E4, without some of the minor peaks including those seen in the aromatic 
region. Fraction 0024i5F was a known compound caylobolide A [see figure 2F for 
fractionation details and figure 2G for 1H-NMR spectra]. [For more on caylobolide A, 
see section 3.2.]. 
 
 





Figure 2G: 1H-NMR of 0024i5F fractionation 
 
Because caylobolide A was so dominant in the two initial fractions (0024H and 0024i) 
as suggested by the 1H-NMRs [figure 2B] and MS [figure 2C], I combined the rest of 
these fractions into 0024Hi in order to purify caylobolide A and to investigate the minor 






2.2.3.3. Fraction 0024Hi 
Fraction 0024Hi was subjected to normal phase column chromatography using a 
gradient of 0-100% MeOH in EtOAc. The tubes were then combined based on MS to 
give eight fractions (0024Hi1-8) [see figure 2H for 1H-NMR]. Fraction 0024Hi8 was 
predominantly caylobolide A, with other minor compound(s), as is seen in the 1H-NMR. 
 
 
Figure 2H: 1H-NMR of 0024Hi Fractions 
 
 
2.2.3.4. Fraction 0024Hi7 
Fraction 0024Hi7, with peaks in the aromatic region that were previously seen, was 
then subjected to reverse phase column chromatography using 50-100% MeOH in H2O 
and flushed with 0-100% EtOAc in MeOH. The tubes were combined based on mass 
spectrometry spectra, yielding five fractions (0024Hi7A-E) [figure 2I]. 1H-NMR spectra 




region, the same peaks that were seen in 0024H6E4 and 0024i5F, and they were 
combined. Mass spectrometry showed values of 743 and 765, along with a few other 
peaks. This fraction (0024Hi7BC) was then sent to PDSP for testing for activity on the 
dopamine D5 receptor, with promising results [tables 2F-2H]. The lower efficacy and 
potency of this fraction compared to the original 0024H and 0024i fractions suggest 
that this is an impure sample. Had it been pure, a higher efficacy (higher inhibition) and 
higher potency (lower IC50) would have been seen compared to 0024H and 0024i. It is 
also possible that the mass of the sample sent in for testing was inaccurate and was 
smaller than the mass used to calculate the efficacy and potency, as the mass of the 
sample sent is approximately the standard error of our scale (~3 mg). However, 
additional peaks in the MS spectra add to the argument of an impure fraction.  
 
DUQ D1 D2 D3 D4 D5 DAT 
0024H 12 5 15 6 70 12 
0024i 15 4 20 -3 50 -20 
0024Hi7BC     51 -14 
Table 2F: % Inhibition of Dopaminergic Receptors and Transporter 
 
DUQ 5HT2A 5HT3 M2 M3 M4 MOR NET SERT σ1 σ2 
0024H 28 -28 -7 -9 10 27 -82 -13 28 42 
0024i 17 -43 3 -2 45 2 -56 -54 39 32 
0024Hi7BC  18      7   
Table 2G: % Inhibition of Other Receptors and Transporters 
 
DUQ D1 D2 D3 D4 D5 DAT 
0024H     2631  
0024i     3029  
0024Hi7BC     2998  










Figure 2J: 1H-NMR of 0024Hi7BC Fractionation 
 
Fraction 0024Hi7BC was then subjected to reverse phase HPLC using a gradient of 40-
100% MeOH in H2O, collecting by 254 nm wavelength, which corresponds to aromatic 
or conjugated systems. One compound eluted at 254 nm, with an additional few peaks 




can be used in its place and peaks can be collected based on 210 nm wavelength as well; 
a future attempt to collect using the new method was halted due to global events.  
 
2.2.3.5. Fraction 0024Hi2 
Fraction 0024Hi2, with peaks in the aromatic region, was subjected to reverse phase 
HPLC using a gradient of 50-100% MeOH in H2O. Fractions were collected based on 
254 nm wavelength, correlating to an aromatic or conjugated system in the molecule, 
however, some of the peaks overlapped, resulting in four semi-purified fractions [figure 
2K]. Fractions 9, 18, 29, and 33 were taken for MS and 1H-NMR [figure 2L]. Fraction 
29, which overlaps with two other peaks, is thought to include barbamide or a similar 
analog. The 1H-NMR [figure 2M] shows an aromatic region with a pattern 
corresponding to a dolaphenine unit, with 1H d at 7.77 ppm, 1H d at 7.51 ppm, and 5H m 
at 7.23 ppm, and MS [figure 2N] includes values of 461 and 483, corresponding to 
barbamide’s mass of 460.   
 
 






















The remainder of 0024Hi2 was subjected to reversed phase column chromatography, 
using a stepwise gradient of 50-100% MeOH in H2O [figure 2O]. Due to lack of time and 
global events, the project was halted at this point. Future steps for this project would 
include isocratic HPLC purifications of fractions 0024Hi2C and 0024Hi2F to isolate the 
compounds seen in peaks 19, 29, and 33.  
 








The dopaminergic system has been implicated in Parkinson’s disease, addiction 
disorders, mood disorders, schizophrenia and more. Specifically, the D1 and D5 
receptors have been implicated in working memory functions and hyperalgesic priming, 
and were shown to be expressed in different types of cancers. These studies were 
completed using knockout models, as there are no known selective D5 ligands to date, 
hindering our understanding of the receptor in our brains and bodies.  
While no dopaminergic compounds were found (yet) from this extract, our lab is 
continuing our efforts to isolate cyanobacterial natural products that show effect on 
dopaminergic receptors, specifically the D5 receptor. These natural products can then 
serve as leads to develop agents that will aid in studying the receptor. 
 
To date, there are no known cyanobacterial compounds that show effect on the 
dopamine receptors. Our lab has shown that cyanobacteria, with their wonderful 
library of natural products, can produce these elusive compounds, and much more. 
This is a call for researchers in academia to continue to study marine cyanobacteria 
and their natural products, to collaborate with labs of different fields, and to take 
advantage of all the tools that we have within our reach, in order to see a fuller and 
more complete picture of these natural products. The PDSP is a free tool, requires 
minimal extract, and can give a bigger picture as to the abilities of the compounds that 





2.4. Experimental Procedures 
2.4.1. Biological Materials 
The cyanobacteria sample was collected in Playa Cas Abao, Curacao [figure 2P] on June 
4, 2015, and given the name CUCA-060415-7. Later, the collection CUSM-060515-3 was 
added, based on the physical appearance of the sample. The sample was described as a 
red filamentous mat in sand [figure 2P], at a depth of 5-10 feet. A small sample was kept 
for microscopic imaging at the CARMABI station the same night [figure 2P]. The sample 
was put into 1:1 sea water and ethanol, with a total volume of 150 mL. Once back in the 
lab, it was kept in -20°C until extraction.  
   
Playa Cas Abao © Google Maps Playa Cas Abao © Google Maps CUCA-060415-7 in the Ocean 
   
CUCA-060415-7 Sample CUCA-060415-7 zoom X7.5 Conrad Digital Scope CARMABI  
 




2.4.2. Extraction  
Prior to extraction, a voucher specimen was taken and is kept in our lab with the ID 
CUCA-060415-7 / DUQ0024. 
The freshly thawed sample was extracted on September 6, 2016, using a mixture of 2:1 
DCM:MeOH. It was soaked five times for 30 minutes each time (5 x 500mL), with a 
sixth soak overnight. The combined extracts were concentrated in vacuo to give 660mg 
of a dark green oil (sample was not fully dried and included sand), 0.56% of dry weight. 
The dry weight of cyanobacteria sample was 118g.  
 
2.4.3. Initial Chromatography 
Extract DUQ0024 was subjected to forced-air column chromatography, using standard 
grade silica gel from Sorbent Technologies (40-63 µM particle distribution, 60Å 
porosity). The solvent system used is detailed in table 2A, each fraction was obtained 
using 500 mL of solvent. 
 
2.4.4. Psychoactive Drug Screening Program (PDSP) Assay 
All of our extracts and initial fractions are sent to the National Institute of Mental 
Health (NIMH) Psychoactive Drug Screening Program (PDSP) to be screened against a 
set of CNS receptors. Compounds or extracts are first subjected to primary radioligand 
binding assays at single concentrations of 10 µM or 10 mg/mL. Compounds that show a 
minimum of 50% inhibition are then tagged for secondary radioligand binding assays to 
determine the equilibrium binding affinity at the specific targets. In secondary binding 




10, 30, 100, 300 nM or ng/mL, 1, 3, 10 µM or mg/mL). [See ref 60-61 for more 
information.] 
A 4 mg sample of each fraction (with the exception of 0024A) was sent to PDSP for a 
complete CNS activity screen [see section 2.2.2. for results].  
 
2.4.5. Chromatography 
2.4.5.1. Fraction 0024H 
Fraction 0024H was subjected to flash chromatography using a normal phase KP-Sil 10 
g column with a gradient of 0-100% MeOH in DCM on a Biotage Isolera™ Prime. Tubes 
were combined to yield seven fractions based on TLC and MS results. 
Fraction 0024H6 was subjected to flash chromatography using a reverse phase SNAP 
C18 12 g column with a gradient of 30-100% MeOH in H2O on a Biotage Isolera™ 
Prime. Tubes were combined to yield five fractions based on TLC and MS results.  
Fraction 0024H6E was subjected to flash chromatography using a normal phase ZIP 
Sphere 5 g column with a gradient of 0-100% MeOH in DCM on a Biotage Isolera™ 
Prime. Tubes were combined to yield five fractions based on TLC and MS results.  
 
2.4.5.2. Fraction 0024i 
Fraction 0024i was subjected to flash chromatography using a normal phase KP-Sil 10 g 
column with a gradient of 0-100% MeOH in DCM on a Biotage Isolera™ Prime. Tubes 




Fraction 0024i5 was subjected to flash chromatography using a normal phase KP-Sil 10 
g column with a gradient of 0-100% MeOH in EtOAc on a Biotage Isolera™ Prime. The 
gradient slope was decreased from 20-60%. Tubes were combined to yield seven 
fractions based on TLC and MS results. 
 
2.4.5.3. Fraction 0024Hi 
Fraction 0024Hi was subjected to flash chromatography using a normal phase KP-Sil 50 
g column with a gradient of 0-100% MeOH in EtOAc on a Biotage Isolera™ Prime. 
Tubes were combined to yield eight fractions based on TLC and MS results.  
Fraction 0024Hi7 was subjected to flash chromatography using a reverse phase SNAP 
C18 12 g column with a gradient of 50-100% MeOH in H2O and flushed with a gradient 
of 0-100% EtOAc in MeOH on a Biotage Isolera™ Prime. Tubes were combined to yield 
five fractions based on MS results. 
Fraction 0024Hi7BC was subjected to high performance liquid chromatography (HPLC) 
using a reverse phase Synergi-fusion 4µ, 150x10mm column from Phenomenex, with a 
gradient of 50-100% MeOH in H2O on a Dionex UltiMate 3000.  
Fraction 0024Hi2 was subjected to high performance liquid chromatography (HPLC) 
using a reverse phase Synergi-fusion 4µ, 150x10 mm column from Phenomenex, with a 
gradient of 50-100% MeOH in H2O on a Dionex UltaMate 3000. Four fractions were 
collected based on peaks of 254 nm wavelength [figure 2L]. After several collections, the 
remainder of the fraction was then subjected to flash chromatography using a reverse 




flushed with a gradient of 0-100% EtOAc in MeOH on a Biotage Isolera™ Prime. Tubes 
were combined to yield six fractions [figure 2O]. 
 
2.4.6. Instruments 
2.4.6.1. NMR Spectroscopy 
NMR spectra were recorded on a Bruker 500 spectrometer at 499.60 MHz for 1H and 
125.62 MHz for 13C.  
Samples were dissolved in CD3OD (with the exception of 0024C-F, dissolved in CDCl3) 
and tested in standard 5mm diameter NMR tube at room temperature. Chemical shifts 
are reported in δ values, [ppm] units, relative to the standard TMS (δ=0), and coupling 
constants reported in [Hz]. [See section 6.1. for more details.] 
 
2.4.6.2. Mass Spectrometry 
Mass spectra were recorded on an Advion Expression Benchtop Mass Spectrometer 






3. Cyanobacterial Natural Products as Antiproliferative 










“Life will always find a way to continue. Always. Life will out.” 





“Life, uh, finds a way.” 




3.1. Natural Products with Antiproliferative Effects 
Cyanobacteria produce many compounds with cytotoxic activity through a variety of 
mechanisms of action. A possible explanation for this is that these compounds provide a 
defense mechanism for the sessile cyanobacteria against mobile predators that may be 
in their surroundings. Cyanobacteria may utilize these cytotoxic compounds by 
excreting them to keep predators at bay, or by producing them only upon disturbance 
leading to cessation of predation. There are a variety of mechanisms by which secondary 
metabolites may act as antiproliferatives such as cell cycle arresters, caspase inhibitors, 
mitochondrial membrane disruptors, lipid permeabilizers, and chemotaxic agents. 
Cell cycle is a delicate mechanism that comprises cell growth and its division into two 
daughter cells. Some substances are able to disturb the normal functioning of this 
mechanism compromising cell viability, a consequence that can be directly related with 
apoptosis. A common cellular damage induced by marine cyanobacteria compounds is 
the disruption of microtubules and actin proteins, which are directly involved in mitosis. 
The most frequent consequence is G2/M phase arrest,62 which is the mechanism of 
action of the dolastatins, including dolastatin 10 [figure 3A]. 
Caspases are a family of cysteine aspartate proteases that act as the central executers of 
apoptosis. Marine cyanobacteria produce several compounds that are capable of 
inducing alterations on caspases as a pathway to induce cell death. Caspase-3 is the 
most studied caspase concerning to apoptosis induced by natural products.62 The 
activity of caspase-3 protein is increased after exposure to symplostatin 1, dolastatin 10, 




Mitochondria have essential functions in aerobic cells, and interferences in its normal 
behavior are crucial to determine cell fate. Dysfunctions in mitochondria imbalances the 
cell redox potential, inducing damages in cell components that can lead to apoptosis. 62 
While no known cyanobacterial compounds have been studied in relation to the 
mitochondria, aurilide [3B],64 a cyclodepsipeptide from the Dolabella auricularia sea 
hare (the same sea hare thought to have produced dolastatin 10), is described to induce 
dysfunction in mitochondria. HeLa cells treated with this compound exhibit 
mitochondria fragmentation.  
The broad spectrum of activities of polyols is thought to be due to their lipid-
permeabilizing effects, due to their amphiphilic nature. The polyhydroxy moieties of 
amphidinols have been shown to permeabilize phospholipid liposomes in the presence 
of cholesterol within the layer.65 The lipid-permeabilizing effect was dependent on the 
cholesterol content, suggesting the direct binding of these compounds to cholesterol, 
leading to pore formation. SAR studies corroborated these results, with the polyene 
region being critical to binding to the lipid bilayer, and the size of the pore being 
dictated by the polyhydroxy region.38 An example of an amphidinol is amphidinol 666 
[figure 3B], which was isolated from marine dinoflagellate, and was shown to have 
sterol-dependent membrane permeability. 
Cancer cell metastasis is enhanced by chemotaxis, the migration of a cell in response to 
a chemical stimulus. Chemotaxis is observed in most organisms, including single-cell 
and multi-cellular organisms. Single-cell organisms like bacteria will approach 
nutritional chemicals but will flee from toxic ones, whereas multicellular organisms 
utilize the phenomenon for single-cell functions, such as the movement of sperm toward 




cells to migrate from one location to another, triggering the development of cancers at 
the new site. Because many cancers are not visible and do not present symptoms until 
they grow sufficiently large, they may hide in other parts of the body for months or 
years, despite the original cancer being eliminated. Therefore, the identification of a 
chemical with the ability to block chemotaxis of cancer cells could provide an effective 
strategy for cancer treatment as an anti-metastatic agent. Nuiapolide67 [figure 3B] 
exhibits anti-chemotactic activity at concentrations as low as 1.3 µM against Jurkat cells, 


























3.2. Cyanobacterial Macrolides as Leads for Antiproliferative 
Agents: Caylobolide A 
Caylobolide A [figure 3C] was isolated serendipitously while attempting to isolate 
dopaminergic compounds in this extract [see section 2.2.3.2. for isolation details, figure 
2F for procedure]. Caylobolide A was isolated as fraction 0024i5F; it was the major 
compound in the extract, accounting for at least 40 mg of the 532 mg extracted, with 
more left unpurified.  
 
Figure 3C: Caylobolide A 
 
3.2.1. Structure Elucidation 
Fraction 0024i5F was subjected to MS analysis, showing m/z values of 785 and 797, 
corresponding to M+23 and M+35, leading to a proposed molecular weight of 762 [figure 
3D].  
Initial 1H-NMR [figure 3E] suggested the compound could be a peptide, as multiple 
peaks in the 3-4 ppm region and in the 1.5-2.5 ppm region correlate to α- and β-protons 
of amino acids. However, after running additional NMR experiments [figures 3F-3J; see 
section 6.2. for more information on NMR experiments], several conclusions were 
made: (1) out of 42 carbons seen, there is only a single carbonyl carbon at 173.55, likely 
an ester, (2) there are nine methines in the 3.5-4.0 ppm region, suggesting multiple 




methyl groups of which two are doublets and one is a triplet. All of this together 
suggested a polyketide structure rather than a peptidic one. 
Based on NMR and MS, we deduced the formula to be C42O11H82; the general structure 
of the molecule would be a hydroxylated lactone, with the carbonyl and ring system 



















































































































































































# δC HSQC δH    δC HSQC δH  
1  173.55 --- C=O  13.00 0.928 CH3 
2  42.30 2.187, 2.397 CH2  13.78 0.937 CH3 
3  26.96 2.246 CH  18.43 1.008 CH3 
4  44.04 1.306, 1.458 CH2  20.78 1.500 CH2 
5  68.51 3.657 CH  20.87 1.509 CH2 
6    CH2  21.41 1.416, 1.602 CH2 
7    CH2  21.51 1.409 CH2 
8    CH2  21.51 1.615 CH2 
9    CH  21.70 1.397, 1.610 CH2 
10    CH2  22.54 1.335 CH2 
11    CH2  26.96 2.246 CH 
12    CH2  29.26 1.355 CH2 
13    CH  32.15 1.128, 1.430 CH2 
14    CH2  36.38 1.499 CH2 
15    CH2  36.56 1.428 CH2 
16    CH2  36.59 1.489 CH2 
17    CH  36.81 1.510 CH2 
18    CH2  36.86 1.510 CH2 
19    CH2  36.89 1.510 CH2 
20    CH2  36.90 1.510 CH2 
21    CH  36.94 1.413 CH2 
22    CH2  36.96 1.687 CH 
23    CH2  36.96 1.425 CH2 
24    CH2  37.05 1.504 CH2 
25    CH  37.80 1.465 CH2 
26    CH2  37.98 1.460 CH2 
27  67.01 4.016 CH m 38.84 1.524, 1.730 CH2 
28    CH2  42.30 2.187, 2.397 CH2 
29    CH  43.36 1.605 CH2 
30    CH2  43.90 1.636 CH2 
31    CH2  44.04 1.323, 1.485 CH2 
32    CH2  67.01 4.016 CH 
33  67.51 3.511 CH  67.51 3.511 CH 
34  38.84 1.524, 1.730 CH2  67.57 3.853 CH 
35  74.32 5.172 CH  68.51 3.657 CH 
36  36.96 1.687 CH  69.20 3.775 CH 
37    CH2  70.59 3.589 CH 
38    CH2  70.73 3.579 CH 
39  22.54 1.335 CH2  70.81 3.570 CH 
40  13.00 0.928 CH3 t 70.96 3.557 CH 
41  13.78 0.937 CH3 d 74.32 5.172 CH 
42  18.43 1.008 CH3 d 173.55  C 






3.2.2. Rediscovering Caylobolide A 
While working on structure elucidation from NMR and MS data, an online search of the 
molecular formula pointed towards the compound being caylobolide A, which was 
described in the original paper68 as a “unique polyketide lactone” isolated in 2002 from 
a sample of Lyngbya majuscula collected in Cay Lobos, Bahamas in 1999. The 
compound contains a 1,3,5-triol, as well as “an unprecedented repeating unit of a 
contiguous pentad of 1,5-diols within the 36-membered macrocycle”, in agreement to 
our structure elucidation efforts thus far.  
A second set of NMR experiments was performed, this time in DMSO, in order to 
compare our NMR data to that in the paper. The 1H-NMR spectrum [figure 3L, table 3B] 





Figure 3K: Caylobolide A 
Color-coded NMR assignment: Because caylobolide A has repeating units, NMR assignments were very 
difficult. For this reason, I have assigned each type of carbon/proton a color, corresponding to possible 



























































#H  Mult J [Hz] δH  
Cay 2002 
#H  Mult J [Hz] 
5.02 1 dt 9.9, 2.9 5.02 1 ddd 9.5, 6.0, 3.0 
4.51 1 d 4.5 *    
4.39 1 d 4.6 *    
4.29 3 m  *    
4.21 4 m  *    
3.79 1 m  3.85 1 dq 12.4, 6.0, 5.0 
3.62 1 m  3.63 1 dq 11.6, 4.5 
3.55 1 m  3.55 1 dq 11.6, 5.0 
3.45 1 m  3.45 1   
2.28 1 m  2.28 1 dd 13.0, 8.5 
2.08 1 m  2.08 1 m 8.5, 4.5 
2.08 1 m  2.05 1 dd 13.0, 4.5 
1.60 1 m  1.60 1 m  
1.16-1.57 53 m  1.58 1   
1.56 1   
1.55 1   
1.54 1   
1.51 1   
1.50 1   
1.45 7   
1.36 1   
1.35 1   
1.32 1   
1.26 6   
1.23 3   
1.13 1 m  1.16 1   
1.03 1 m      
0.85 3 m  0.88 3 t 6.7 
0.85 3 m  0.85 3 t 6.0 
0.85 3 m  0.83 3 t 7.0 
3.34 H2O       
2.51 DMSO       
Table 3B: 1H-NMR Comparison of 0024i5F and Caylobolide A in DMSO 
 
*The original paper had an error in the table and did not show values of the 4.0-5.0 ppm 
range. However, the 1H-NMR spectra in the original paper’s supplemental information 
was nearly identical to our 1H-NMR spectra and did show the peaks in the 4.0-5.0 ppm 




3.2.3. Micro Electron Diffraction 
As the original paper did not resolve the complete stereochemistry of the molecule, we 
sought to do so via micro electron diffraction. Using the newly developed micro electron 
diffraction (MED) technique utilizing cryo-electron microscopy (CEM), we attempted to 
determine the absolute configuration of caylobolide A.  
CEM is a relatively new method that utilizes the transmission electron microscope for 
chemical structure elucidation, allowing structure determination of large and/or 
dynamic macromolecular assemblies in solution without the need to crystallize the 
molecule. Instead, it uses cryogenics, freezing the molecules in solution, thus also 
protecting them from the electron beams.  
MED is a technique similar to X-ray diffraction (XRD) which uses CEM to determine 
molecular structures of small molecules in atomic resolutions from nanocrystals only a 
few molecule layers thick. Because it makes use of electron beams, which are less 
damaging than X-rays, high-quality diffraction data is producible from crystals one 
billion times smaller than what is necessary for XRD. The best resolution to date is 
~1Å.69 This method would allow us to determine the relative stereochemistry of 
caylobolide A. The relative stereochemistry from CEM could then be combined with the 
data of the four stereocenters already determined to obtain the absolute stereochemistry 
of all stereocenters in the molecule.  
In order to obtain the best diffraction data, the product needed to be crystallized. In the 
first crystallization attempt, the product was simply dissolved in DCM and allowed to 
dry in the refrigerator. A second attempt was made using heated water. In both cases, 




When sent for testing, both samples had formed crystals that were too small to obtain 
sufficient data. We hypothesized that the molecule is likely too flexible to orient itself in 
a single direction to form large enough crystals for successful diffraction patterns [see 
figure 3M for images taken]. Also, throughout the project, the lab had been having 
technical difficulties with the instrument, and after these two attempts, the project came 
to an end.  
 
   
Caylobolide A crystal X19000 Single diffraction pattern 0° tilt All spots -30° to 30° projected 
 






3.2.4. Activity of Caylobolide A 
Caylobolide A has been reported to exhibit cytotoxicity toward the human colon tumor 
cell line HCT-116 with an IC50 of 9.9 µM, and did not show anti-fungal activity against 
two strands of Candida.68 After being isolated in our lab, it was sent to the PDSP for 
screening against the full panel of receptors, with no significant activity detected [tables 
3C and 3D].  
 
DUQ D1 D2 D3 D4 D5 DAT 
0024H 12 5 15 6 70 12 
0024i 15 4 20 -3 50 -20 
0024i5F 9 -5 -9 -14 20 -14 
Table 3C: % Inhibition of Dopaminergic Receptors and Transporter 
 
DUQ 5HT2A 5HT3 M2 M3 M4 MOR NET SERT σ1 σ2 
0024H 28 -28 -7 -9 10 27 -82 -13 28 42 
0024i 17 -43 3 -2 45 2 -56 -54 39 32 
0024i5F 31 -24 8 1 9 -5 -6 -16 40 47 





3.3. Experimental Procedures 
 
3.3.1. Biological Materials: See section 2.4.1. 
 
3.3.2. Extraction: See section 2.4.2. 
 
3.3.3. Initial Chromatography: See section 2.4.3. 
 
3.3.4. Psychoactive Drug Screening Program Assay: See section 2.4.4. 
 
3.3.5. Chromatography 
Fraction 0024i was subjected to flash chromatography using a normal phase KP-Sil 10 g 
column with a gradient of 0-100% MeOH in DCM on a Biotage Isolera™ Prime. Tubes 
were combined to yield seven fractions based on TLC and MS results. 
Fraction 0024i5 was subjected to flash chromatography using a normal phase KP-Sil 10 
g column with a gradient of 0-100% MeOH in EtOAc on a Biotage Isolera™ Prime. The 
gradient slope was decreased from 20-60%. Tubes were combined to yield seven 







3.3.6.1. NMR Spectroscopy 
NMR spectra were recorded on a Bruker 500 spectrometer at 499.60 MHz for 1H and 
125.62 MHz for 13C.  
Experiments for caylobolide A (1H, 13C, 1H-COSY, HSQC, HMBC, HSQC-TOCSY, 
NOESY, CLIP-HSQC, DOSY) were recorded on a Bruker 500 spectrometer at 500 MHz 
for 1H and 125.73 MHz for 13C at Carnegie Melon University. 
Samples were dissolved in CD3OD or DMSO-d6 and tested in standard 5mm diameter 
NMR tube at room temperature. Chemical shifts are reported in δ values, [ppm] units, 
relative to the standard TMS (δ=0), and coupling constants reported in [Hz]. [See 
section 6.1. for more details.] 
 
3.3.6.2. Mass Spectrometry 
Mass spectra were recorded on an Advion Expression Benchtop Mass Spectrometer 
using Electro Spray Ionization (ESI).  
 
3.3.6.3. Micro Electron Diffraction 
The microscope is a ThermoFisher Tecnai TF20 equipped with a field emission gun and 
a TVIPS XF416 camera, with a grid in a Gatan 626 cryo-holder. Data collection was 
attempted using both room temperature and cryo-temperatures via cooling the holder 
with liquid nitrogen after putting the grid in it. The software controlling the diffraction 




4. Cyanobacterial Natural Products for Neglected 










“If you think you are too small to make a difference, try spending the 






4.1. Neglected Tropical Diseases 
Neglected tropical diseases (NTDs) are a diverse group of communicable diseases that 
prevail in tropical and subtropical conditions in 149 countries, affecting more than one 
billion people, and costing developing economies billions of dollars every year. 
Populations living in poverty, without adequate sanitation, and in close contact with 
infectious vectors and domestic animals and livestock are those worst affected.70 
Effectiveness of available medication is diminished by the emergence of resistant 
pathogens and severe side effects associated with therapy. Because these diseases do not 
pose a significant threat to the population of developed countries and the financial 
return is minimal, the pharmaceutical industry is less focused on developing new agents 
for these diseases. Instead, non-governmental organizations and academic research labs 
are motivated to investigate and contribute lead molecules for treatments of these 
diseases. Our lab is among the handful of academic research labs that explores natural 
products of plant, fungal, and marine cyanobacteria origin in the search for new drug 
leads using assays against various NTDs, including malaria, leishmaniasis, and Chagas 
disease. 
 
4.1.1. Neglected Tropical Diseases: Malaria, Leishmaniasis, and Chagas 
Malaria is caused by Plasmodium parasites and spread by female Anopheles mosquito 
bites. Plasmodium falciparum is the deadliest of the five species of the malaria parasite 
that can infect humans. Vaccines are available, but treatment for infection is more 
difficult than prevention. The current recommended first-line treatment by the WHO is 




trypanosomiasis, is caused by the Trypanosoma cruzi parasite. It is spread by 
Triatominae insects, also known as kissing bugs. The disease is curable if treated 
immediately after infection; benznidazole and nifurtimox are both effective if started 
immediately, but their effectiveness drops to less than 60% for those in the chronic 
phase of the disease, about 1-2 months after initial infection. Leishmaniasis is caused by 
Leishmania parasites and is spread by female phlebotomine sandflies. For some species 
of Leishmania, a single dose of amphotericin B can cure up to 95% of infections. For 
other species, such as L. donovani, the most severe visceral form of Leishmaniasis, an 
effective drug has yet to be discovered. Currently, strategies to prevent transmission of 
these infections via the insect vector include insecticide spraying and long-lasting 
insecticide-treated bed nets. However, these are not 100% effective. 
 
4.1.2. Natural Products for Treatment of Neglected Tropical Diseases 
There are several approved antiprotozoal drugs of natural origin, including quinine, 
artemisinin, amphotericin B, and paromomycin [figure 4A]. The Quechua of Peru, 
Bolivia, and Ecuador were the first to discover the benefits of the cinchona tree to halt 
shivering due to low temperatures. In the 17th century it was used to treat the shivers 
brought on by the febrile phase of malaria, and it was found to cure the disease. It was 
only in 1820 that quinine was discovered as the active compound in the tree bark, which 
is still used today to treat malaria. Artemisinin,71 a sesquiterpene used to treat malaria, 
was isolated in 1972 from the plant Artemisia annua, an herb traditionally used in 
Chinese medicine. Amphotericin B,72 a polyketide used to treat leishmaniasis since 




collected from the soil around the Orinoco River in Venezuela. Its complete stereo 
structure was determined in 1970 by X-ray crystallography of the N-iodoacetyl 
derivative, and its first synthesis achieved in 1987.73 Paromomycin, isolated in the 1950s 

















4.1.3. Marine Cyanobacterial Natural Products as Leads for Antiprotozoal 
Agents 
While these frontline antiprotozoal drugs are of terrestrial origin, marine natural 
products can also provide an important source of effective lead compounds. Protozoa 
are single-celled eukaryotic organisms that evolved about 1.5 billion years ago and 
require an aquatic habitat to thrive.74 Cyanobacteria have evolved alongside these 
organisms, and in some cases have even developed a mutual symbiosis; the amoeba 
Paulinella chromatophora appears to have acquired autotrophy via relatively recent 
endosymbiosis of a cyanobacterium.75 With their ability to chemically and 
biosynthetically produce a plethora of different structural classes of compounds, and 
their evolution alongside protozoal organisms, cyanobacteria likely have the potential to 
produce potent and selective lead compounds with antiprotozoal activity.  
In recent years, a growing number of studies have tested cyanobacterial extracts against 
a panel of tropical parasites, including those responsible for malaria, leishmaniasis, and 
Chagas disease, with encouraging results. Several marine cyanobacterial natural 
products with antiprotozoal activity have been reported, including [figure 4B] 
gallinamide A, carmabin A, dolastatin 10, dolastatin 15, dragonamide A, calothrixin A, 
and herbamide B, with IC50 values between 100 pM to 7.7 µM against P. falciparum and 
L. donovani [table 4A].76-81 Unfortunately, most of the compounds mentioned also 
showed general cytotoxicity and were not subjected to further testing. Gallinamide A, 
also known as symplostatin 4, showed no detectable toxicity to cancer cell lines, 
including NCI-H460 human lung tumor cells and Neuro-2a mouse neuroblastoma 




P. falciparum. Treatment of P. falciparum-infected red blood cells with gallinamide A 
resulted in the generation of a swollen food vacuole phenotype of the parasite. The 
mechanism of action was suggested to be inhibition of falcipains, cysteine proteases that 
are involved in hemoglobin hydrolysis of the host in the parasites’ food vacuole. Overall, 
gallinamide A led to a significant reduction of parasites at nanomolar concentrations. It 
is suggested through analog design that the methoxypyrrolinone unit is necessary and 
responsible for this anti-malarial activity.77, 79, 82  
 
IC50 [µM] P. falciparum L. donovani T. cruzi Vero Cells HeLa HT-29 
gallinamide A77-79 0.05a, 8.4b 9.3 inactive 10.4 12 53 
carmabin A80 1.4b   9.8   
dolastatin 1080 100 pMa      
dolastatin 1580 0.20a      
calothrixin A80 0.058b      
dragonamide A80 7.7b 6.5  67.8   
herbamide B81  5.9     
a P. falciparum 3D7 
b P. falciparum W2 
 HeLa Cervical Carcinoma 
HT-29 Colon Adenocarcinoma 




















dragonamide A calothrixin A 
 






In our efforts to find new drug leads for NTDs, our lab discovered the novel natural 
product naranjamide [figure 4C]. Naranjamide is a linear peptide containing six amino 
acids, including a terminal N,N-dimethyl valine and a C-terminal dolaphenine. 
 
 
Figure 4C: naranjamide 
 
4.2.1. Isolation Procedure 
An orange cyanobacterium sample collected by hand using SCUBA in Portobelo, 
Panama was extracted using a 2:1 DCM:MeOH mixture to yield a crude extract (extract 
code 2002, mass 4.2 g). The extract was tested for its antiprotozoal activity [table 4B] 
and was found to inhibit P. falciparum growth by 82.6 % at a concentration of 10 
µg/mL. The extract was then fractionated by forced-air column chromatography and the 
fraction obtained with 1:1 EtOAc:MeOH (fraction 2002H, mass 69.4 mg) showed growth 
inhibition of both P. falciparum (97.5 %) and T. cruzi (75.0 %) at a concentration of 10 
µg/mL. Further fractionation by C18 Sep-Pak yielded a fraction eluting with 80 % 
MeOH in H2O (fraction 2002H4, mass 8.5 mg), which showed growth inhibition of P. 
falciparum (79.6 %) and T. cruzi (81.5 %) at a concentration of 10 µg/mL, with an IC50 
of 6.36 µg/mL for T. cruzi. This fraction was then purified with reverse-phase HPLC 
using a gradient of 50-100% AcN in H2O (fraction 2002H4D) to yield 0.8 mg of pure 




fractionation procedure]. Due to lack of material and difficulty in obtaining 
reimportation permits for the natural product, the pure natural product was not 
screened following its isolation.  
Fraction L. donovani P. falciparum T. cruzi MCF-7 
2002 4.7 82.6 16.7 28.2 
2002H 13.7 97.5 75.0 13.6 
2002H4 NT 79.6 81.5 NT 
Table 4B: Antiprotozoal Activity of 2002 Fractionation (% Growth Inhibition) 
 
 
Figure 4D: Purification of Naranjamide 
 
4.2.2. Structure Elucidation  
The structure of naranjamide was determined in our lab using extensive NMR 
experiments [figures 4E-4H; see section 6.2. for more information on NMR 
experiments] as well as high resolution mass spectrometry and MS/MS experiments 
[figure 4I]. The stereo-configurational analysis by Marfey’s was not completed due to 









































































































The HRMS of fraction 
2002H4D gave an M+ of 
685.44576, matching a 
theoretical mass of 685.44695, 









The structure of naranjamide was determined as a linear peptide containing six amino 
acids [Figure 4C]. The C-terminus is composed of condensed phenylalanine and 
cysteine residues, called dolaphenine; the thiazole ring is formed by condensation of the 
cysteine sulfur and phenylalanine carbonyl, followed by dehydration, and oxidative 
decarboxylation [figure 4J]. The same dolaphenine unit is seen in other cyanobacterial 
natural products, such as dolastatin 10 [figure 4B]. Naranjamide is also capped on the 
N-terminus with an N,N-dimethyl valine, which is present in a large number of bioactive 
cyanobacterial peptides, like gallinamide A [figure 4B]. Of the six amino acids present in 
the molecule, three are N-methylated, another common characteristic of cyanobacterial 
natural products [figure 4B].  
 
Figure 4J: Proposed Thiazole Formation Mechanism 
 
The NMR spectra of naranjamide were very convoluted. This is likely due to the slowly 
free-rotating benzyl in the dolaphenine unit, in addition to the rigidity brought on by the 
N-methylations [figure 4K]. Looking into the HSQC [Figure 4F], there are four benzylic 
protons, one pair similar to but with a weaker signal than the other two. This led us to 
believe that the spectrum was actually made up of two pseudo-atropisomers; the 




depending on the position of the aromatic ring in comparison to the rest of the 
molecule, namely the N-methyl groups and residue side chains. As the initial isolation 
was of a single peak on the HPLC, we think that the spectrum represents pseudo-
atropisomers, and not two distinct atropisomers that are separable. Atropisomers are 
stereoisomers arising because of hindered rotation about a single bond, where energy 
differences due to steric strain or other contributors create a barrier to rotation that is 
high enough to allow for isolation of individual conformers. A way to verify this and to 
deconvolute the NMR spectra would have been to increase the temperature while 
collecting NMR data.  
 
 
Figure 4K: Rotation of Dolaphenine on Naranjamide 
 








4.2.3. Synthesis of Naranjamide and Analogs 
A total synthesis of the molecule was attempted for two main reasons. First, NMR 
spectra were very convoluted [discussed in section 4.2.2.], and synthesis with known 
precursors would allow to verify the NMR assignments as well as determine the 
stereochemistry, as cyanobacteria are known to include D-amino acids as well. Second, 
more material would allow extensive biological testing, to determine efficacy and 
potency, mechanism of action, and cytotoxic activity of this novel molecule.  
A small-scale synthesis of naranjamide and several analogs, including a nonmethylated 
and a fully N-methylated, were attempted in our lab, and the products were tested for 
activity against L. donovani, P. falciparum, and T. cruzi.  
 
4.2.4. Activity of Naranjamide and Analogs 
Synthetic naranjamide and two synthetic analogs were tested for activity against L. 
donovani, P. falciparum, and T. cruzi, as well as cytotoxicity against MCF-7 and Vero 
cancer cell lines [table 4C]. Synthetic naranjamide was found to possess antimalarial 
activity with an IC50 of 2.8 µM against the W2 chloroquine-resistant strain of P. 
falciparum, and an IC50 of 9.2 µM against T. cruzi; it was inactive against L. donovani. 
Synthetic naranjamide was also shown to have cytotoxic activity, with a 90.3 % 
inhibition of growth for MCF-7 cancer cell line. The fully methylated analog of 
naranjamide [figure 4L] was found to have lost activity for malaria, while maintaining 
cytotoxicity. The nonmethylated analog of naranjamide [figure 4L] was found to be 
almost as potent and efficacious at inhibiting P. falciparum growth; however, activity 




activity, which led to our conclusion that this molecule was not generally toxic, but was 
selectively killing the malaria parasite, while the natural product may be effective 
against P. falciparum because of general cytotoxic activity. 
This preliminary data showing efficacy, potency, and selectivity made the 
nonmethylated naranjamide analog an ideal candidate for further investigation as a lead 
for an antimalarial drug. Further testing to evaluate the activity, selectivity, and 
mechanism of action of naranjamide and its synthetic analogs needed to be completed. 
For this, and for verifying the complete structure of naranjamide, a large-scale synthesis 




Figure 4L: Fully Methylated (top) and Non-Methylated (bottom) Naranjamide Analogs 
 
Molecule Leishmania Malaria Chagas MCF-7 Vero 
Synthetic 
Naranjamide 









Out of range 14.46 µM 
9.3 µg/mL 
12.23% GI 0 - 
Methylated 
Naranjamide 
>200 µg/mL 57.08 µM 
39.9 µg/mL 
3.27% GI 0 - 





4.2.5. Synthesis of Naranjamide: Old Method 
The synthesis of naranjamide was initially envisioned as a convergent synthesis [figure 
4M], with a methylated tripeptide (KN4me) comprising the right piece of the molecule 
condensing with a dipeptide (KN6) of the left piece of the molecule. Synthesis [figure 
2N] involved building the BOC-protected tripeptide using BOC-protected isoleucine, 
methyl-ester valine, and dolaphenine unit, followed by methylation of the tripeptide, 
and BOC-deprotection, as well as building a left piece using N,N-dimethyl valine and 
methyl-ester valine, followed by deprotection of the methyl-ester. The synthesis of the 
nonmethylated analog [figure 2O] would be similar, without the methylation reaction. 
 
 
















































































In synthesizing the intermediate KN3me, methylation of the tripeptide was difficult. 
According to mass spectrometry, it is likely that there were partial methylations of the 
peptide, with masses reflecting single and double methylations, as well as failure of 
methylation, in addition to the desired trimethylated peptide KN3me [figure 4P]. To get 
full methylation of the tripeptide, 10 equivalents of base and 25 equivalents of methyl 
iodide were used, with several reaction batches requiring multiple methylation 
attempts. Previous attempts were made increasing the equivalents of base and methyl 
iodide, however, overmethylation occurred, methylating the thiazole nitrogen. 
In both the original and nonmethylated analogs, deprotection of the BOC group to yield 
KN4me and KN4 was difficult, and several attempts were made to get higher yields. The 
harsh acidic conditions of TFA in DCM hydrolyzed the peptide seemingly at the same 
rate of deprotection, leaving similar amounts of the free amine, the single amino acids, 
and the unreacted KN3me and KN3, respectively, as seen on mass spectrometry [figure 
4P). Shorter reaction times as well as low temperatures were used, but proved 
inefficient. Using HCl in MeOH did not show improved results.  
Two attempts at the final coupling reaction of KN4me and KN6 were made, but were 
unsuccessful. Mass spectroscopy after an initial attempt using EDC and HOBt with 
DIPEA in DCM showed the reaction did proceed at all. A second attempt using HATU in 
DMF with DIPEA also failed, and with DMF being very difficult to remove, the reaction 
mixture turned into an inseparable oil and was tossed. Several attempts were made to 
couple KN4 and KN6 of the nonmethylated analog. While coupling secondary amines is 
known to be difficult or provide lower yields, coupling of the primary amine KN4 with 




like EDC/HOBt, CIP/HOBt, and HATU, in DCM with DIPEA [table 4D]. Likely, the 








Figure 4P: MS of Naranjamide Intermediates: Old Method 
 
Coupling Reagents Yield of Final Coupling 
HATU/DIPEA in DMF83 0% (N7me) 
EDC/HOBt/DIPEA in DCM 0% (Nme7), 17% (N7) 
CIP/HOBt/DIPEA in DCM84 6% (N7) 
HATU/DIPEA in DCM 15% (N7) 






Ultimately, a question of racemization arose, questioning whether the harsh basic 
methylation conditions were causing racemization of KN3me. It was then that a 
seemingly pure N4me product was injected onto the HPLC, showing multiple peaks 
[figure 4Q], indicating that racemization was indeed occurring. Looking into the 
literature, any of the methyl ester deprotections using sodium hydroxide,85 methylations 
using sodium hydride, or BOC deprotections using TFA or HCl, could have caused a 
number of racemizations at nearly every step of the tripeptide synthesis. At this point, 
the synthesis method was revised.  
 
 







4.2.6. Synthesis of Naranjamide: New Method 
To avoid racemization, an alternate synthetic pathway was developed which included N-
methylated, FMOC-protected amino acids [figure 4R]. FMOC-protected and N-
methylated-FMOC-protected amino acids are readily available in large quantities at 
affordable prices due to use in automated peptide synthesis. Premethylated amino acids 
allow to avoid the harsh basic conditions of the methylation reaction, and FMOC 
protection requires 4-methylpiperidine, a softer and more specific base, for 
deprotection. The peptide was then assembled from the dolaphenine unit to the N,N-
dimethyl valine, with five peptide coupling steps. 
N-methylated dolaphenine (KN1), required for synthesizing the natural product, was 
synthesized by protecting the dolaphenine amine with BOC, followed by methylation 
(KN2), and BOC deprotection (KN3). Without BOC protection, the primary amine 
would have been overmethylated to form a quaternary nitrogen with three methyl 
groups attached; each methyl group would have made the nitrogen more reactive. 
The methylation of dolaphenine proved to be difficult; the reaction was extremely 
sensitive to humidity and moisture, providing yields between 0-90% depending on 
moisture levels in the lab, despite efforts to dry glassware and reagents, and running the 
reaction under inert atmosphere. The BOC deprotection proved difficult yet again, 
however, as a single amino acid, the reaction could run for a longer duration without 








































Because dolaphenine has a single chiral center, potential racemization occurring during 
the previous two reactions could potentially lead to two enantiomers, inseparable by 
HPLC. However, the subsequent coupling reaction with N-methyl valine (KN4) would 
create diastereomers, allowing separability. 
From there, three additional peptide coupling reactions with subsequent FMOC 
deprotections would be used to add N-methyl-isoleucine, valine, and finally N,N-
dimethyl valine. Two attempts were made at the first coupling reaction, condensing N-
methyl dolaphenine and N-methyl valine: the first, using CIP/HOBt in DCM, which gave 
the product in low yield (~15%), the second, using CIP/HOBt in DCM with DIPEA, 
which did not give any product at all.  
Due to time restraints (and global events at this time), the project was halted after the 







4.2.7. Synthesis of Nonmethylated Naranjamide: New Method 
The nonmethylated analog of naranjamide was also synthesized [figure 4S]. The 
synthetic scheme consisted of four coupling reactions, with subsequent FMOC-
deprotections, similar to those of the natural product synthesis, starting with the 
coupling of dolaphenine and FMOC-valine (KuN1), and followed by couplings of FMOC-
isoleucine (KuN3), FMOC-valine (KuN5), and N,N-dimethyl valine (KuN7). In this 
synthesis, the peptide couplings were of primary amines versus of secondary amines, 
making the couplings faster and more efficient. HOBt and EDC were used in coupling 
reactions, with yields of 70-80%. As the peptide grew it became more hygroscopic and 
was also slower to dissolve in DCM for the coupling reactions, so a few drops of MeOH 
were added to the penultimate and final steps of the reaction sequence.  
Initially, the FMOC-protected intermediates were chosen to perform NMR 
characterizations on, however, the FMOC, much like the dolaphenine, skewed the NMR 
and made it more difficult to read. Therefore, after purifying the FMOC-protected 
intermediates to >95%, they were deprotected and purified via flash column 
chromatography. Due to time restraints and (global events at this time), the free amine 
intermediates were not fully purified on HPLC, and the resulting MS and NMR spectra 
are not reflective of a pure product, with the NMRs difficult to interpret. [See figures 


















































4.2.8. Structure-Activity Relationship of Naranjamide Analogs 
The three analogs tested for antiprotozoal activity and general cytotoxicity showed 
varying results [see table 4C]. While the natural product showed efficacy against P. 
falciparum and T. cruzi as well as general cytotoxicity, methylation in just one 
additional amino acid led to complete inactivity. Meanwhile, the nonmethylated analog 
showed selective activity against P. falciparum, without detectable cytotoxicity. These 
differences in activities are likely due to the methylation pattern.  
The antimalarial activity is likely due to the dolaphenine, while the methylation pattern 
leads to cytotoxic activity. The natural product, while having antimalarial activity, could 
be hindering a normal cellular activity by way of the amide methylations; a regular cell 
cannot digest this molecule, and it incorporates into and destroys normal protein-
protein interactions. The nonmethylated product, however, while having the same 
antimalarial activity in the protozoal cells, would not harm human (cancer) cells because 
the human body can hydrolyze and digest the peptide, as it includes regular amide 
bonds.  
This can be easily verified by synthesizing additional analogs of naranjamide. The 
syntheses of the two analogs can be altered by using different amino acids in the 
addition sequence, allowing to create an analog library. Specifically, it would be 
interesting to create analogs without the dolaphenine unit, as well as with a benzyl 
(phenylalanine) or a thiazole moiety alone, to determine its requirement for activity, as 
was seen with the crucial methoxypyrrolinone moiety in gallinamide A. These analogs 






Neglected tropical diseases effect over one billion people and cost developing economies 
billions of dollars each year.70 Available treatments are often ineffective, with severe side 
effects or resistance development. With warming climates and frequent travel, more and 
more populations will be susceptible to these diseases. Development of new and 
effective therapies are therefore an important task. 
Nature has provided us with a plethora of natural products, some of which have shown 
encouraging results when tested against the protozoa responsible for these diseases. We 
have discovered a novel cyanobacterial natural product with activity against P. 
falciparum, the malaria-causing protozoa. In order to confirm its structure and to test 
its activity and mechanism of action against the parasite, a total synthesis was 
attempted. Synthesis of a nonmethylated analog was also attempted, with the product 
displaying selectivity for P. falciparum and no detectable general cytotoxicity. This 
natural product is one of many cyanobacterial natural products that have been found to 




4.4. Experimental Procedures 
4.4.1. Synthetic Materials 
All reagents and HPLC-grade solvents were purchased from Sigma Aldrich or Thermo 
Fisher and used without further purification, unless stated otherwise. Dolaphenine was 
purchased from Chemscene. 




HATU hexafluorophosphate azabenzotriazole tetramethyl uranium 
HOBt hydroxybenzotriazole 
TFA trifluoroacetic acid 
 
4.4.2. General Procedure for Peptide Coupling 
4.4.2.1. For Primary Amines 
FMOC-protected carboxylic acid (1.1eq) was added with HOBt (1.2 eq) and EDC (1.2 eq) 
to DCM, stirring for 30 minutes at 0°C. After 30 minutes, the amine∙HCl (1 eq) was 
added with DIPEA (3 eq). The reaction was stirred overnight, warming to room 
temperature. The reaction mixture was then diluted with DCM, washed with citric acid, 
NaHCO3, and H2O. It was then dried in vacuo, and the product purified via Biotage 






4.4.2.2. For Secondary Amines 
FMOC-protected carboxylic acid (2 eq) was added with HOBt (1 eq) and DIPEA (6 eq) to 
DCM, stirring for 5 minutes at RT. After 5 minutes, the secondary amine (1 eq) was 
added with CIP (2 eq). The reaction was stirred for 3 hours at RT. The reaction mixture 
was then diluted with DCM, and washed with citric acid, NaHCO3, and H2O. It was then 
dried in vacuo, and the product purified via Biotage Isolera™ column chromatography 
using a normal phase KP-Sil 10 g column.  
 
4.4.3. General Procedure for FMOC Deprotection 
FMOC-protected amine was dissolved in 10:1 v/v DCM:4-methylpiperidine solution (~1 
mL per 100 mg), and the reaction stirred for one hour. The reaction mixture was then 
dried in vacuo, and the product purified via Biotage Isolera™ column chromatography 
using a normal phase KP-Sil 10 g column. 
 
4.4.4. General Procedure for HPLC Purification 
The product was loaded onto a reverse phase Synergi-fusion 4µ, 150x10 mm column 
from Phenomenex on a Dionex UltaMate 3000, starting with 70% MeOH in H2O for 1.5 
minutes, then a gradient of 70-100% MeOH in H2O over 15 minutes, followed by 100% 





4.4.5. Reaction Procedures: Nonmethylated Naranjamide (KuN7) 
4.4.5.1. KuN1: (9H-fluoren-9-yl)methyl ((S)-3-methyl-1-oxo-1-(((S)-2-phenyl-1-
(thiazol-2-yl)ethyl)amino)butan-2-yl)carbamate 
Reaction was carried out per section 4.4.2.1.; the product eluted at 2% MeOH in DCM. It 
was then purified per section 4.4.4. with retention time of 15.5 minutes. 

























4.4.5.2. KuN2: (S)-2-amino-3-methyl-N-((S)-2-phenyl-1-(thiazol-2-yl)ethyl)butanamide 
Reaction was carried out per section 4.4.3.; the product eluted at 12% MeOH in DCM. 
KuN2: white solid. Yield: 90%, 57 mg, 0.19 mmol.  
 
 KuN2 
 # H 
[ppm] 












1 N - - 
2 7.723 0.94, d, 3.1 142.2 
3 7.171 5.95, m 119.1 
4 S - - 
5 C4 - 171.5 




1.06, dd, 7.1 
1.06, dd, 7.1 
41.2 
8 C4 - 136.5 
9 7.171 5.95, m 128.5 
10 7.171 5.95, m 129.3 
11 7.171 5.95, m 126.9 
12 7.171 5.95, m 129.3 
13 7.171 5.95, m 128.5 







15 - - 170.8 
16 3.496 0.92, d, 5.0 59.4 
17 2.113 0.98, m, 6.7 30.6 
18 0.75 2.86, d, 6.7 18.8 
19 0.85 3.00, d, 6.7 16.8 
20 - - - 




























4.4.5.3. KuN3: (9H-fluoren-9-yl)methyl ((2S,3S)-3-methyl-1-(((S)-3-methyl-1-oxo-1-
(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)butan-2-yl)amino)-1-oxopentan-2-
yl)carbamate 
Reaction was carried out per section 4.4.2.1.; the product eluted at 2% MeOH in DCM. It 
was then purified per section 4.4.4. with retention time of 17.0 minutes. 
KuN3: white solid. Yield: 66%, 78 mg, 0.12 mmol. 
This product was very jelly-like and difficult to try down. It was left under air 
overnight and dried into a fine powder which blew out onto the bench, losing a 
significant amount of it. Some of it was recovered and repurified. 
 
 [M+H+] 639.5 














Reaction was carried out per section 4.4.3.; the product eluted at 3% MeOH in DCM. 







calc 461.1958  
 





4.4.5.5. KuN5: (9H-fluoren-9-yl)methyl ((S)-3-methyl-1-(((2S,3S)-3-methyl-1-(((S)-3-
methyl-1-oxo-1-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)butan-2-yl)amino)-
1-oxopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate 
Reaction was carried out per section 4.4.2.1.; the product eluted at 5% MeOH in DCM. It 
was then purified per section 4.4.4. with retention time of 17.4 minutes. 




















Reaction was carried out per section 4.4.3.; the product eluted at 7% MeOH in DCM. 







calc 538.2828  
 







4.4.5.7. KuN7: nonmethylated naranjamide: (2S,3S)-2-((S)-2-((S)-2-(dimethylamino)-
3-methylbutanamido)-3-methylbutanamido)-3-methyl-N-((S)-3-methyl-1-oxo-
1-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)butan-2-yl)pentanamide 
Reaction was carried out per section 4.4.2.1, with 1:1 MeOH:DCM. It was then purified 
via Biotage Isolera™ column chromatography using a 5g ZIP Sphere column; the 
product eluted at 25% MeOH in DCM. 
KuN7: white solid. Yield: 22%, 11 mg, 0.017 mmol.  
The column used for purification malfunctioned during the loading; an unknown 






calc 665.3819  




4.4.6. Reaction Procedures: Naranjamide (KN10) 
4.4.6.1. KN1: tert-butyl (S)-(2-phenyl-1-(thiazol-2-yl)ethyl)carbamate 
Salted amine was deprotonated via liquid-liquid extraction with NaOH, and then 
reacted with BOC2O (2 M in DCM) in DCM for 2 hours. It was then dried in vacuo, and 
purified via flash column chromatography; the product eluted at 20% EtOAc in 
Hexanes. 























4.4.6.2. KN2: tert-butyl (S)-methyl(2-phenyl-1-(thiazol-2-yl)ethyl)carbamate 
BOC-protected dolaphenine (KN1, 1 eq) was stirred in THF under N2 for one hour. After 
one hour, MeI (8 eq) was added, and stirred under N2 at 0°C for an additional 30 
minutes. Then, NaH (3 eq) was carefully added to the solution, and the solution was 
stirred under N2 at 0°C overnight. The reaction mixture was then diluted with EtOAc 
and neutralized to pH7 with HCl. The organic layer was then dried in vacuo, and the 
product extracted with DCM from water. It was then dried in vacuo, and purified via 
flash column chromatography; the product eluted at 15% EtOAc in Hexanes. 
























 KN1 KN2 














1 N - N - 
2 7.77 1H, d, 7.80 1H, m 
3 7.51 1H, m 7.61 1H, m 
4 S - S - 
5 C4 - C4 - 














8 C4 - C4 - 
9 





14 NH - 2.73 3H, s 
15 1.32 9H, “d” 1.34 9H, “dd” 







4.4.6.3. KN3: (S)-N-methyl-2-phenyl-1-(thiazol-2-yl)ethan-1-amine 
Product (3) is dissolved in DCM, and TFA is added 1:1 (1 mL per 10 mg product). 
Reaction is run for 30 minutes, or as needed determined by TLC. The reaction mixture 
was then neutralized with NaOH, the organic layer extracted with DCM. It was then 
dried in vacuo, and purified via flash column chromatography, the product eluting at 
25% EtOAc in Hexanes. 












4.4.6.4. KN4: (9H-fluoren-9-yl)methyl methyl((S)-3-methyl-1-(methyl((S)-2-phenyl-1-
(thiazol-2-yl)ethyl)amino)-1-oxobutan-2-yl)carbamate 
Reaction was carried out as per section 2.2.1.2. (General Procedure for Peptide Coupling 
for Secondary Amines). It was then purified via flash column chromatography, the 
product eluting at 40% EtOAc in Hexanes. 
KN4: colorless oil. Yield: 16%, 62 mg, 0.11 mmol. 
Not pure, possibly two diastereomers. Purification was not completed due to global 














4.4.7.1. NMR Spectroscopy 
Experiments for intermediates were recorded on a Bruker 500 spectrometer at 499.60 
MHz for 1H and 125.62 MHz for 13C.  
Experiments for Naranjamide (1H, 13C, 1H-COSY, HSQC, HMBC, HSQC-TOCSY, 
NOESY, CLIP-HSQC, DOSY) were recorded on a Bruker 500 spectrometer at 500 MHz 
for 1H and 125.73 MHz for 13C at Carnegie Melon University. 
Samples were dissolved in CD3OD and CDCl3 and tested in standard 5mm diameter 
NMR tube at room temperature. Chemical shifts are reported in δ values, [ppm] units, 
relative to the standard TMS (δ=0), and coupling constants reported in [Hz]. [See 
section 6.1. for more details.] 
 
4.4.7.2. Mass Spectrometry 
Mass spectra were recorded on an Advion Expression Benchtop Mass Spectrometer 







4.4.8.1. Leishmania (Leishmania donovani) Bioassay 
Axenically grown (cell free) amastigotes of Leishmania donovani WR2801, a kind gift 
from Max Grogl (Experimental Therapeutics Division, Walter Reed Army Institute of 
Research, Silver Spring, MD, USA), were used to assess parasite growth and survival. 
Samples were tested in duplicates at 10 g/mL. The results were expressed as a 
percentage of growth inhibition (GI) compared to controls. Samples that showed over 
70% GI were considered active and were then assayed at four different concentrations 
(0.08, 0.4, 2, and 10 g/mL) to determine IC50 values. Amphotericin B was used as a 
positive control with an IC50 value response of 80-120 ng/mL.  
 
4.4.8.2. Chagas (Trypanosoma cruzi) Bioassay 
Trypanosoma cruzi bioassays were performed using a colorimetric method, and the 
growth inhibition of the parasite was assessed by the expression of the reporter gene for 
-galactosidase (-Gal) in the recombinant Tulahuen clone C4 of T. cruzi from The 
American Type Cell Collection (ATCC). Assays were performed in duplicates on the 
amastigote stage, which is the intracellular form of the parasite infecting African green 
monkey kidney (Vero) cells, exposed during 120 h to different concentrations (10, 2, and 
0.4 g/mL) of the test compounds at 37C under an atmosphere of 5% CO2 in air. The 
resulting color from the cleavage of chlorophenol red--D-galactoside (CPRG) by -Gal 
expressed by the parasite was measured at 570 nm. The concentration that inhibited 




density values and compared with the untreated controls. Nifurtimox was used as a 
positive control (IC50 2-5 g/mL). 
 
4.4.8.3. Malaria (Plasmodium falciparum) Bioassay 
Antiplasmodial activity was evaluated using a fluorometric method based on the 
detection of parasite DNA with the fluorochrome PicoGreen. The chloroquine-resistant 
strain Indochina W2 (a generous gift of The Walter Reed Army Institute of Research, 
Silver Spring, MD) of Plasmodium falciparum was used for the crude extract and 
subsequent fractions. For the synthetic product, the chloroquine-sensitive HB3 strain 
obtained from the Malaria Research and Reference Reagent Resource Center (MR4, 
Manassas, VA, USA) was used. All initial screenings were performed at 10g/mL. The 
IC50 value was calculated by normal regression of the resulting inhibition percentages at 
0.08, 0.4, 2, and 10 g/mL. Parasites were maintained in vitro by a modification of the 
method of Trager and Jensen, synchronizing the parasites with alanine. Chloroquine 
was used as a positive control (IC50 80-100 nM for W2 and 15-26 nM for HB3).  
 
4.4.8.4. Cytotoxicity Assay 
The reduction of tetrazoliom MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was used to assess the viability of cells. 5×103 cells in 100 
µL of media per well are cultured in 96-well plates and let incubate at 37°C for 24 hours 
before adding 50 µL of different concentrations of the target molecules. For screening, 




with equal volume of the vehicle was used. Cells are incubated 48 hours longer before 
performing the MTT assay. Absorbance values were determined in a Synergy HT plate 
reader (BioTek Instruments, Winooski, VT) employing a 570 nm test wavelength and a 
650 nm reference filter. The IC50 was calculated using the Data Analysis Wizard 
complement of Excel 2000 (Microsoft, Seattle, USA). 
 
4.4.8.5. MCF-7 Cell Line Assay 
The MCF-7 mammalian breast cancer cell line was obtained from ATCC. On the day 
prior to the bioassay, 5×103 cells were seeded in a final volume of 100 µL/well in 96-well 
plates and incubated with RPMI-1640 supplemented with gentamicin (0.05 mg/mL), L-
glutamine (GIBCO; 2 mM), NaHCO3 (4.6 mM), HEPES buffer (25 mM), and FBS (10%) 
at 37°C. For each bioassay, 100 µL of the extract was diluted in culture media, added to 
the cells, and incubated for 48 h at 37°C. Cells were fixed with tricholoroacetic acid 
(50%), and treated with sulphorhodamine B (0.4%), which was allowed to react for 15-
30 min at 22°C. The cells were then rinsed with acetic acid (1%), dried, and treated with 
Tris-HCl (10 mM, pH 7) for 15 min. Color intensity was read at 570 nm. The positive 





5. Conclusions  
Humans have used plants, plant extracts, and pure natural products as medicines to 
treat pain and disease since at least 5000 BC when we have evidence of the first written 
recording of their use. Natural products are produced by organisms to aid their own 
overall fitness, allow communication between species, and deter and attract prey. These 
compounds have evolved to interact with various biological targets, as their producers 
evolved alongside their target organisms, leading to highly selective and potent 
compounds. After centuries of terrestrial pharmacognosy, scientists started looking in 
the ocean and other aquatic environments for natural products. One major benefit of 
natural products from these sources is that for natural products to be effective in water, 
these compounds would need to be especially potent. 
Marine cyanobacteria evolved billions of years ago and today higher order species with 
large genomes have the ability to produce a plethora of compounds, including peptides 
and macrolides. These natural products have been shown to have effects on human CNS 
receptors, including the dopamine receptors, as well as antiproliferative effects, against 
cancers, bacteria, and protozoa responsible for diseases like malaria and Chagas’ 
disease.  
 
Dopamine has a central role in the nervous system and is involved in a variety of 
functions and disorders. Of the five dopamine receptors, the D5 receptors is perhaps the 
least researched, as its similarity and scarcity compared to the D1 receptor makes 
specified targeting of it more difficult. While cyanobacteria have been shown to 




products, many natural product scientists do not screen for dopaminergic activity, or 
any biogenic amine receptor activity, as part of their standard bioassays. In this 
research, we have shown that cyanobacteria can produce various compounds which bind 
to dopaminergic receptors, and this additional screening can be of great contribution to 
the field of natural product drug discovery. While a pure natural product responsible for 
this affinity has not yet been determined, our research is ongoing. Once isolated, this 
selective natural product will allow us to gain insight on the role of the D5 receptor and 
the molecular determinants that confer selectivity. Future studies could develop a probe 
to determine the localization of these receptors, and an analog library will allow 
identification of the pharmacological effects of agonistic, antagonistic, and inverse 
agonist behavior at the receptor. 
 
During the search for the compound in this extract with D5 affinity, the serendipitous 
rediscovery of caylobolide A allowed us to learn about additional structure elucidation 
capabilities. Caylobolide A was discovered originally in 2002, however, its full 
stereochemistry has never been resolved due to the flexibility of the molecule and the 
isolated positions of the hydroxyl groups in the macrolide ring. Micro electron 
diffraction, a newer technique utilizing the cryo-electron microscope, would allow for 
the determination of the relative stereochemistry of the molecule; combining this 
information with the four known stereocenters would allow determination of the 
absolute configuration of the molecule. Caylobolide A purified from the extract provided 
crystals that were too small to obtain sufficient data, likely due to the flexibility of the 




as acetylation or benzoylation, adding rigidity to the molecule. This technique could 
help solve the configuration of this and many other similar molecules.  
 
Another option for determining the configuration of the molecule would be a total 
synthesis, which is what was attempted with naranjamide. Naranjamide was discovered 
in a Panamanian extract, and showed potential as an antimalarial agent, with its 
synthetic nonmethylated analog showing selective toxicity against the malarial protozoa 
P. falciparum. The NMR spectra of the natural product were convoluted, likely due to a 
dolaphenine unit, creating two pseudo-atropisomers. A synthesis using amino acids 
with known configuration would allow determination of the stereoconfiguration of the 
molecule, as cyanobacteria are known to occasionally incorporate D-amino acids as well 
as L-amino acids. The initial synthetic route showed a racemized mixture of products 
and was ultimately changed. While these racemized products were unwanted, they could 
potentially help study the target and determine the configuration needed for achieving 
optimal selectivity and activity. An alternate synthetic route was then designed for the 
natural product and the nonmethylated analog. The synthetic products can then be 
tested for activity and mechanism of action, helping to understand the selectivity of the 
nonmethylated analog and its cellular target. 
 
This thesis presents my work combining natural products chemistry with medicinal 
chemistry to better understand the interactions of compounds with their biological 
targets. Isolation and structure elucidation are the tools of natural products chemistry to 




medicinal chemistry to understand and optimize those interactions. The projects 
presented here are a combination of the two fields and display how natural products and 





6. General Experimental Procedures 
 
6.1. Synthetic Materials 
All reagents and HPLC-grade solvents were purchased from Sigma Aldrich or Thermo 
Fisher and used without further purification, unless stated otherwise.  
 
6.2. Nuclear Magnetic Resonance 
Nuclear magnetic resonance (NMR) is one of the most powerful tools for structure 
elucidation. Along with data received from UV, IR, MS, and other analytical techniques, 
NMR aids in determining the final structure of a compound in question. 
NMR experiments generally divide into two groups: one-dimensional (1D) and two-
dimensional (2D). A 1D spectrum is an expression of the signal versus time or frequency 
(obtained after performing a Fourier transform over time). This type of experiment 
examines one type of nucleus, for example 1H or 13C [see figure 3E for example]. A 2D 
spectrum includes two different types of nuclei, and two dimensions of frequency 
(again, obtained after Fourier transform). This type of experiment allows to study 
correlations between chemical shifts of same or different nuclei, for example 1H and 1H, 
or 1H and 13C. Correlations of bonds between two to five atoms apart can be examined, 
depending on the type of experiment.  





6.2.1. HSQC: 13C-1H Correlation 
HSQC (Hetereonuclear Single Quantum Correlation) correlates 13C nuclei with directly 
attached (coupled) protons; these are one-bond (1JCH) couplings [see figure 3G for 
example]. The frequency domains are of different nuclei, so there is no apparent 
diagonal or symmetry. The essential difference between HSQC and HMQC is that, while 
the HSQC experiment is carbon detected, the HMQC is proton detected. Since there are 
great discrepancies between proton and carbon in their relative abundances and 
sensitivities, HMQC is greatly preferred today. 
 
6.2.2. COSY: 1H-1H Correlation 
COSY (COrrelation SpectroscopY) is the simplest 2D experiment. The peaks shown on 
the experiment correlate coupled protons [see figure 3H for example]. 
 
6.2.3. HMBC: 1H-13C Long Range Correlation 
HMBC (Heteronuclear Multiple Bond Coherence) is proton detected and capitalizes on 
these two- and three-bond couplings providing an extremely powerful (and sometimes 
cluttered) spectrum [see figure 3I for example]. In essence, carbon-carbon correlations 
are indirectly obtained. Both 2JCH and 3JCH couplings are present, and interpretation can 







TOCSY (Totally Correlated SpectroscopY) show all coupled nuclei within the same spin 
system. This experiment has the same appearance as a COSY, with proton showing on 
both axes, but will show all protons for the spin system. For longer mixing times, all 




HSQC-TOCSY is a type of “hybrid” 2D correlation experiment that combines features of 
two simpler 2D experiments. HSQC-TOCSY correlates one-bond H-C couplings (HSQC) 
but shows these correlations throughout an entire spin system (TOCSY) [see figure 3J 
for example]. This experiment simplifies complex carbohydrate and peptide systems 






6.3. Mass Spectrometry  
Mass spectrometry (MS) determines the molecular weight of a compound. The 
commonly used electron-impact (EI) mode works by bombarding molecules in a vapor 
phase with a high-energy electron beam, causing molecules to ionize, and then records 
the result as a spectrum of positive or negative ions, which have been separated on the 
basis of mass/charge (m/z) [see figure 3D for example]. 
 
6.4. Column Chromatography 
Liquid column chromatography separates molecules based on different characteristics 
they have, such as size, polarity, or chirality. The chromatographic strategies used in our 
lab use polarity to separate molecules, and date back at least as far back as 1996, with 
the discovery of barbamide by the Gerwick lab.86 The general procedure for 
chromatographic purification uses normal phase flash column chromatography, eluting 
with a non-polar to polar solution, using hexanes, ethyl acetate, and methanol, followed 
by reverse phase column chromatography using methanol or acetonitrile in water, and 
lastly using a more precise reverse phased HPLC with methanol or acetonitrile in water.  
 
6.4.1. Flash Column Chromatography: Biotage Isolera™ Prime 
The Biotage Isolera™ Prime allows automated separation of molecules, based on their 
polarity. It also allows detection of the molecules in the sample using UV technology; 
210 nm and 254 nm wavelengths were used to detect C=X double bonds and conjugated 





6.4.2. High Performance Liquid Chromatography: Dionex UltiMate 3000 
The Dionex UltiMate 3000 allows automated, high-precision separation of molecules, 
based on their polarity. It also allows detection and quantification of the molecules in 
the sample using UV technology; 210 nm, 254 nm, 310 nm, and 410 nm were used to 
detect C=X double bonds, conjugated molecules, and pigments, respectively. 
Reverse phase HPLC using the Dionex UltiMate 3000 were performed, using a Synergi-
fusion 4µ, 150x10mm column from Phenomenex [see figure 2K for example].  
 
6.5. Thin Layer Chromatography 
Prior to column chromatography, thin layer chromatography (TLC) was performed for 
samples to determine methodology. TLC results were determined using UV light, 
followed by staining with ninhydrin solution for detection of amines and amides (1.5 g 
ninhydrin in 100 mL BuOH and 3 mL AcOH), or with vanillin solution for all molecules 
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